



Induction immunosuppression in adults 
undergoing liver transplantation: a 
network meta-analysis 
 
Best, L. M., Leung, J., Freeman, S. C., Sutton, A. J., Cooper, N. 
J., Milne, E. J., Cowlin, M., Payne, A., Walshaw, D., Thorburn, 
D., Pavlov, C. S., Davidson, B. R., Tsochatzis, E., Williams, N. R. 
& Gurusamy, K. S. 
 
Published PDF deposited in Coventry University’s Repository  
 
Original citation:  
Best, LM, Leung, J, Freeman, SC, Sutton, AJ, Cooper, NJ, Milne, EJ, Cowlin, M, Payne, 
A, Walshaw, D, Thorburn, D, Pavlov, CS, Davidson, BR, Tsochatzis, E, Williams, NR & 
Gurusamy, KS 2020, 'Induction immunosuppression in adults undergoing liver 





DOI    10.1002/14651858.CD013203.pub2 






Copyright © and Moral Rights are retained by the author(s) and/ or other 
copyright owners. A copy can be downloaded for personal non-commercial 
research or study, without prior permission or charge. This item cannot be 
reproduced or quoted extensively from without first obtaining permission in 
writing from the copyright holder(s). The content must not be changed in any way 
or sold commercially in any format or medium without the formal permission of 




Cochrane Database of Systematic Reviews
 
Induction immunosuppression in adults undergoing liver
transplantation: a network meta-analysis (Review)
 
  Best LMJ, Leung J, Freeman SC, Sutton AJ, Cooper NJ, Milne EJ, Cowlin M, Payne A, Walshaw D,
Thorburn D, Pavlov CS, Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS
 
  Best LMJ, Leung J, Freeman SC, Sutton AJ, Cooper NJ, Milne EJ, Cowlin M, Payne A, Walshaw D, Thorburn D, Pavlov CS,
Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS. 
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. 




Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)
 








Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
















CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 44
ADDITIONAL TABLES.................................................................................................................................................................................... 80
APPENDICES................................................................................................................................................................................................. 89
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 91
DECLARATIONS OF INTEREST..................................................................................................................................................................... 91
SOURCES OF SUPPORT............................................................................................................................................................................... 92
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 92
NOTES........................................................................................................................................................................................................... 92
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
[Intervention Review]
Induction immunosuppression in adults undergoing liver
transplantation: a network meta-analysis
Lawrence MJ Best1, JeBrey Leung2, Suzanne C Freeman3, Alex J Sutton3, Nicola J Cooper3, Elisabeth Jane Milne4, Maxine Cowlin5,
Anna Payne6, Dana Walshaw7, Douglas Thorburn8, Chavdar S Pavlov9, Brian R Davidson1, Emmanuel Tsochatzis8, Norman R Williams10,
Kurinchi Selvan Gurusamy1,9
1Division of Surgery and Interventional Science, University College London, London, UK. 2Medical School, University College London,
London, UK. 3Department of Health Sciences, University of Leicester, Leicester, UK. 4Centre for Trust, Peace and Social Relations,
Coventry University, Coventry, UK. 5PSC Support, London, UK. 6HPB and Liver Transplant Surgery, Royal Free London NHS Foundation
Trust, London, UK. 7Acute Medicine, Barts and The London NHS Trust, London, UK. 8Sheila Sherlock Liver Centre, Royal Free Hospital
and the UCL Institute of Liver and Digestive Health, London, UK. 9Center for Evidence-Based Medicine, 'Sechenov' First Moscow State
Medical University, Moscow, Russian Federation. 10Surgical & Interventional Trials Unit (SITU), UCL Division of Surgery & Interventional
Science, London, UK
Contact address: Kurinchi Selvan Gurusamy, Division of Surgery and Interventional Science, University College London, Rowland Hill
Street, London, NW32PF, UK. k.gurusamy@ucl.ac.uk.
Editorial group: Cochrane Hepato-Biliary Group
Publication status and date: New, published in Issue 1, 2020.
Citation: Best LMJ, Leung J, Freeman SC, Sutton AJ, Cooper NJ, Milne EJ, Cowlin M, Payne A, Walshaw D, Thorburn D,
Pavlov CS, Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS. Induction immunosuppression in adults undergoing liver
transplantation: a network meta-analysis. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD013203. DOI:
10.1002/14651858.CD013203.pub2.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Liver transplantation is considered the definitive treatment for people with liver failure. As part of post-liver transplantation management,
immunosuppression (suppressing the host immunity) is given to prevent graH rejections. Immunosuppressive drugs can be classified into
those that are used for a short period during the beginning phase of immunosuppression (induction immunosuppression) and those that
are used over the entire lifetime of the individual (maintenance immunosuppression), because it is widely believed that graH rejections
are more common during the first few months aHer liver transplantation. Some drugs such as glucocorticosteroids may be used for both
induction and maintenance immunosuppression because of their multiple modalities of action. There is considerable uncertainty as to
whether induction immunosuppression is necessary and if so, the relative eBicacy of diBerent immunosuppressive agents.
Objectives
To assess the comparative benefits and harms of diBerent induction immunosuppressive regimens in adults undergoing liver
transplantation through a network meta-analysis and to generate rankings of the diBerent induction immunosuppressive regimens
according to their safety and eBicacy.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials
Registry Platform, and trials registers until July 2019 to identify randomised clinical trials in adults undergoing liver transplantation.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or status) in adults undergoing liver transplantation. We
excluded randomised clinical trials in which participants had multivisceral transplantation and those who already had graH rejections.
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Data collection and analysis
We performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio (OR), rate ratio, and
hazard ratio (HR) with 95% credible intervals (CrIs) based on an available case analysis, according to National Institute of Health and Care
Excellence Decision Support Unit guidance.
Main results
We included a total of 25 trials (3271 participants; 8 treatments) in the review. Twenty-three trials (3017 participants) were included in
one or more outcomes in the review. The trials that provided the information included people undergoing primary liver transplantation
for various indications and excluded those with HIV and those with renal impairment. The follow-up in the trials ranged from three to
76 months, with a median follow-up of 12 months among trials. All except one trial were at high risk of bias, and the overall certainty of
evidence was very low. Overall, approximately 7.4% of people who received the standard regimen of glucocorticosteroid induction died
and 12.2% developed graH failure.
All-cause mortality and graH failure was lower with basiliximab compared with glucocorticosteroid induction: all-cause mortality (HR
0.53, 95% CrI 0.31 to 0.93; network estimate, based on 2 direct comparison trials (131 participants; low-certainty evidence)); and graH
failure (HR 0.44, 95% CrI 0.28 to 0.70; direct estimate, based on 1 trial (47 participants; low-certainty evidence)). There was no evidence
of diBerences in all-cause mortality and graH failure between other induction immunosuppressants and glucocorticosteroids in either the
direct comparison or the network meta-analysis (very low-certainty evidence).
There was also no evidence of diBerences in serious adverse events (proportion), serious adverse events (number), renal failure, any
adverse events (proportion), any adverse events (number), liver retransplantation, graH rejections (any), or graH rejections (requiring
treatment) between other induction immunosuppressants and glucocorticosteroids in either the direct comparison or the network meta-
analysis (very low-certainty evidence). However, because of the wide CrIs, clinically important diBerences in these outcomes cannot be
ruled out. None of the studies reported health-related quality of life.
Funding: the source of funding for 14 trials was drug companies who would benefit from the results of the study; two trials were funded
by neutral organisations who have no vested interests in the results of the study; and the source of funding for the remaining nine trials
was unclear.
Authors' conclusions
Based on low-certainty evidence, basiliximab induction may decrease mortality and graH failure compared to glucocorticosteroids
induction in people undergoing liver transplantation. However, there is considerable uncertainty about this finding because this
information is based on small trials at high risk of bias. The evidence is uncertain about the eBects of diBerent induction
immunosuppressants on other clinical outcomes, including graH rejections.
Future randomised clinical trials should be adequately powered, employ blinding, avoid post-randomisation dropouts (or perform
intention-to-treat analysis), and use clinically important outcomes such as mortality, graH failure, and health-related quality of life.
P L A I N   L A N G U A G E   S U M M A R Y
Medical interventions to prevent early gra4 rejection a4er liver transplantation
What is the aim of this Cochrane Review?
Liver transplantation is the main treatment option for people with severe advanced liver disease. When organs or tissues are transplanted
from one person (organ donor) to another (organ recipient), the body of the organ recipient identifies the donor organ (or graH) as a
foreign body and initiates a response against it in a way similar to the natural body defence mechanism against infections (immune
response). This can sometimes lead to rejection or failure of the donor liver, which can result in the death of the organ recipient. Various
medical interventions (immunosuppressive regimen) are used either alone or in combination to prevent rejection. The combination of
interventions used in the first few months aHer liver transplantation (induction immunosuppressive regimen) is oHen diBerent from the
combination used for the rest of the patient's life (maintenance immunosuppression). It is unclear which induction immunosuppressive
regimen aHer liver transplantation is the most eBective.
The review authors collected and analysed all relevant research studies to answer this question and found 25 randomised clinical trials
(studies in which participants are randomly assigned to one of two groups). During analysis of data, authors used standard Cochrane
methods, which allow comparison of only two treatments at a time. Authors also used advanced techniques that allow comparison of
multiple treatments simultaneously (usually referred to as 'network (or indirect) meta-analysis').
Date of literature search
July 2019
Key messages
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Only one of the 25 studies was conducted without flaws and most of the studies were small in terms of the number of participants
included. Because of this, there is high or very high uncertainty in the obtained analysis results in this review. Overall, a drug called
basiliximab may halve the number of deaths and graH failures in people who have had a liver transplant compared to the standard
induction immunosuppressive regimen of glucocorticoids.
The funding source was unclear in nine studies. Commercial organisations funded 14 of the studies. There were no concerns regarding the
source of funding for the remaining two trials.
What was studied in the review?
This review studied adults of any sex, age, and ethnic origin, who underwent liver transplantation for various reasons. Participants were
given diBerent induction immunosuppressive agents or no induction immunosuppressive agents. The review authors excluded studies
in people who underwent other organ transplants (such as kidney transplant) in addition to the liver, and studies in which people had
already developed graH rejection. The average age of participants, when reported, ranged from 48 years to 62 years. The administered
induction immunosuppressive groups included glucocorticosteroids, anti-thymocyte globulin, basiliximab, or dacluzimab either alone or
in combination with glucocorticosteroids. The review authors wanted to gather and analyse data on death, graH failure, quality of life,
serious and non-serious adverse events, kidney failure, time to liver retransplantation, and graH rejections.
What were the main results of the review?
The 25 studies included a small number of participants in total (3271 participants). Study data were sparse. Twenty-three studies with 3017
participants altogether provided data for analyses. The follow-up of participants in the trials ranged from three to 76 months: the average
follow-up in the trials was 12 months. The review shows that:
- seven out of every 100 people died and 12 out of every 100 people developed graH failure;
- compared with the standard induction immunosuppression of glucocorticosteroids, basiliximab may halve the number of deaths and
graH failure; however this information is based on small studies with flaws. Therefore, there is a lot of uncertainty about the eBect of
basiliximab;
- the evidence is uncertain about the eBects of diBerent induction immunosuppressants on other clinical outcomes, including graH
rejections;
- none of the trials reported health-related quality of life;
- future well-designed trials are needed.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Induction immunosuppression in adults undergoing liver transplantation




Follow-up period: median 12 months (range 3 to 76 months)
Network geometry plots: Figure 1; Figure 2
Outcomes Basiliximab plus glucocorticosteroids Anti-thymocyte globulin plus glucocor-
ticosteroids
Basiliximab




21 fewer per 1000




54 more per 1000





35 fewer per 1000
(51 fewer to 5 fewer)




Based on 627 participants (3 RCTs) Based on 152 participants (3 RCTs) Based on 131 participants (2 RCTs)




55 fewer per 1000




116 more per 1000





23 fewer per 1000
(84 fewer to 143
more)




Based on 627 participants (3 RCTs) Based on 152 participants (3 RCTs) Based on 47 participants (1 RCT)







1 fewer per 1000






























































































































































Based on 528 participants (2 RCTs)











(93.4 per 100 partici-
pants)
-
Based on 148 participants (1 RCT)
-




1 fewer per 1000





Based on 381 participants (1 RCTs)
- -




485 more per 1000





306 fewer per 1000
(758 fewer to 352
more)
Very low1,2,3 Very low1,2,3
Glucocorticosteroids
1612 per 1000
(161.2 per 100 partici-
pants)
-
Based on 93 participants (1 RCT) Based on 47 participants (1 RCT)




6 fewer per 1000







































































































































































32 fewer per 1000




77 more per 1000





19 fewer per 1000
(121 fewer to 115
more)




Based on 627 participants (3 RCTs) Based on 152 participants (3 RCTs) Based on 131 participants (2 RCTs)




38 more per 1000





130 fewer per 1000
(232 fewer to 135
more)




Based on 147 participants (1 RCTs)
-
Based on 47 participants (1 RCT)
*Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted
median risk of the control group.
**Ranking is not provided because of the uncertainty in the ranking.
CrI: credible interval; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1Downgraded one level because the trial(s) included in the analysis was/were at high risk of bias.
2Downgraded one level because the sample size was small.
3Downgraded one level because the credible intervals were wide (includes clinical benefit and harms).






























































































































































Figure 1.   A high resolution image is available at https://doi.org/10.5281/zenodo.3605006. The network plots showing the primary outcomes
for which network meta-analysis was performed. The size of the node (circle) provides a measure of the number of trials in which the particular
Intervention was included as one of the intervention groups. The thickness of the line provides a measure of the number of direct comparisons
between two nodes (interventions). A high resolution image is available at: http://doi.org/10.5281/zenodo.3524994. Abbreviations
ATG = anti-thymocyte globulin
Steroids = glucocorticosteroids






























































































































































Figure 2.   A high resolution image is available at https://doi.org/10.5281/zenodo.3605010. The network plots showing the secondary outcomes
for which network meta-analysis was performed. The size of the node (circle) provides a measure of the number of trials in which the particular
Intervention was included as one of the intervention groups. The thickness of the line provides a measure of the number of direct comparisons
between two nodes (interventions). A high resolution image is available at: http://doi.org/10.5281/zenodo.3524994. Abbreviations
ATG = anti-thymocyte globulin
Steroids = glucocorticosteroids






























































































































































Summary of findings 2.
Induction immunosuppression in adults undergoing liver transplantation




Follow-up period: median 12 months (range 3 to 76 months)
Network geometry plots: Figure 1; Figure 2

















74 per 1000 53 per 1000
(31 to 85)
21 fewer per 1000
(43 fewer to 11 more)
Very low1,2,3
Anti-thymocyte globulin plus gluco-
corticosteroids




74 per 1000 128 per 1000
(52 to 317)
54 more per 1000
(22 fewer to 243 more)
Very low1,2,3
Basiliximab




74 per 1000 39 per 1000
(23 to 69)
35 fewer per 1000
(51 fewer to 5 fewer)
Low1,2
Daclizumab plus glucocorticosteroids




74 per 1000 99 per 1000
(58 to 180)
25 more per 1000
(16 fewer to 106 more)
Very low1,2,3
Anti-thymocyte globulin




74 per 1000 89 per 1000
(43 to 192)
15 more per 1000
(31 fewer to 118 more)
Very low1,2,3





























































































































































(2 RCTs; 350 participants) (0.60 to 3.06)
Network estimate
(44 to 227) (30 fewer to 153 more)
No active intervention




74 per 1000 56 per 1000
(13 to 232)
18 fewer per 1000
(61 fewer to 158 more)
Very low1,2,3









122 per 1000 67 per 1000
(31 to 142)
55 fewer per 1000
(92 fewer to 19 more)
Very
low1,2,3,4
Anti-thymocyte globulin plus gluco-
corticosteroids




122 per 1000 238 per 1000
(57 to 1000)
116 more per 1000








122 per 1000 99 per 1000
(38 to 265)
23 fewer per 1000
(84 fewer to 143 more)
Low1,2
Daclizumab plus glucocorticosteroids




122 per 1000 156 per 1000
(60 to 459)
33 more per 1000








122 per 1000 109 per 1000
(25 to 475)
13 fewer per 1000








122 per 1000 148 per 1000
(53 to 461)
25 more per 1000
(69 fewer to 339 more)
Very
low1,2,3,4
No active intervention (only mainte-
nance immunosuppression)




122 per 1000 93 per 1000
(15 to 562)
30 fewer per 1000
(108 fewer to 439 more)
Very
low1,2,3,4
Health-related quality of life None of the trials reported this outcome.





































































































































































376 per 1000 376 per 1000
(289 to 470)
1 fewer per 1000
(87 fewer to 94 more)
Very low1,2,3
Daclizumab plus glucocorticosteroids




376 per 1000 343 per 1000
(282 to 410)
33 fewer per 1000
(94 fewer to 34 more)
Very low1,2,3
Serious adverse events (number of events)
Total studies: 2
Total participants: 185
Anti-thymocyte globulin plus gluco-
corticosteroids




934 per 1000 586 per 1000
(360 to 954)
348 fewer per 1000








934 per 1000 1042 per 1000
(752 to 1431)
107 more per 1000











26 per 1000 29 per 1000
(11 to 72)
3 more per 1000
(15 fewer to 46 more)
Very low1,2,3





(1 RCT; 381 participants)
OR 0.98
(0.02 to 38.67)
971 per 1000 970 per 1000
(451 to 999)
1 fewer per 1000




































































































































































971 per 1000 971 per 1000
(946 to 984)
0 more per 1000
(24 fewer to 14 more)
Very low1,2,3
Daclizumab




971 per 1000 899 per 1000
(530 to 978)
29 fewer per 1000
(29 fewer to 7 more)
Very low1,2,3












306 fewer per 1000
(758 fewer to 352 more)
Very low1,2,3
Glucocorticosteroids Reference
Anti-thymocyte globulin plus gluco-
corticosteroids








485 more per 1000
(60 fewer to 1215 more)
Very low1,2,3









29 per 1000 23 per 1000
(1 to 861)
6 fewer per 1000
(28 fewer to 832 more)
Very low1,2,3
Daclizumab plus glucocorticosteroids




29 per 1000 36 per 1000
(19 to 70)
7 more per 1000



































































































































































(3 RCTs; 627 participants) (0.62 to 1.16)
Network estimate
(198 to 316) (87 fewer to 31 more)
Anti-thymocyte globulin plus gluco-
corticosteroids




285 per 1000 362 per 1000
(216 to 541)
77 more per 1000
(69 fewer to 256 more)
Very low1,2,3
Basiliximab




285 per 1000 267 per 1000
(164 to 400)
19 fewer per 1000
(121 fewer to 115 more)
Very low1,2,3
Daclizumab plus glucocorticosteroids




285 per 1000 277 per 1000
(227 to 334)
8 fewer per 1000
(59 fewer to 48 more)
Very low1,2,3
Anti-thymocyte globulin




285 per 1000 271 per 1000
(165 to 413)
14 fewer per 1000
(121 fewer to 128 more)
Very low1,2,3
Daclizumab




285 per 1000 199 per 1000
(131 to 290)
87 fewer per 1000
(154 fewer to 5 more)
Very low1,2,3
No active intervention




285 per 1000 272 per 1000
(9 to 937)
13 fewer per 1000
(276 fewer to 652 more)
Very low1,2,3









265 per 1000 303 per 1000
(158 to 495)
38 more per 1000
(108 fewer to 230 more)
Very low1,2,3
Basiliximab




265 per 1000 135 per 1000
(33 to 400)
130 fewer per 1000
(232 fewer to 135 more)
Very low1,2,3
Daclizumab plus glucocorticosteroids




265 per 1000 253 per 1000
(195 to 321)
12 fewer per 1000



































































































































































265 per 1000 389 per 1000
(125 to 783)
124 more per 1000
(140 fewer to 518 more)
Very low1,2,3
Daclizumab




265 per 1000 268 per 1000
(104 to 530)
3 more per 1000
(162 fewer to 265 more)
Very low1,2,3
*Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted
median risk of the control group.
**Ranking is not provided because of the uncertainty in ranking.
CrI: credible interval; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1Downgraded one level because the trial(s) included in the analysis was/were at high risk of bias.
2Downgraded one level because the sample size was small.
3Downgraded one level because the credible intervals were wide (includes clinical benefit and harms).
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B A C K G R O U N D
Description of the condition
The liver is a complex organ with multiple functions including
carbohydrate metabolism, fat metabolism, protein metabolism,
drug metabolism, synthetic functions, storage functions, digestive
functions, excretory functions, and immunological functions (Read
1972). The liver can be aBected by acute or chronic diseases.
The main causes of chronic liver disease are non-alcohol-related
fatty liver disease, alcohol misuse, and viral infections such as
viral hepatitis B and C (Younossi 2011; Dam Fialla 2012; Ratib
2014). Other causes include autoimmune hepatitis, primary biliary
cholangitis, primary sclerosing cholangitis, haemochromatosis,
alpha-1 antitrypsin deficiency, and cryptogenic cirrhosis (cirrhosis
of unknown cause) (Dam Fialla 2012; Ratib 2014).
Chronic liver disease caused 10,000 deaths in 2009 in the
UK and 40,000 deaths in 2015 in the USA (Davies 2012; CDC
2018). While the age-standardised mortality due to cirrhosis
(advanced liver fibrosis) has decreased from 18.6 per 100,000
per year to 15.6 per 100,000 per year overall, the proportion of
all deaths caused by cirrhosis is increasing in some countries
such as in the UK (Lozano 2012; Murray 2013). Cirrhosis has
two phases: an asymptomatic 'compensated cirrhosis' phase
and a 'decompensated cirrhosis' phase characterised by clinical
manifestations, such as upper gastrointestinal bleeding from
varices, ascites, encephalopathy, non-obstructive jaundice, or
renal failure (D'Amico 2006). The median survival in people with
compensated liver disease varies and can be more than 10 years,
while for people with decompensated liver disease it is less
than two years (D'Amico 2006). The only definitive treatment for
decompensated liver cirrhosis is liver transplantation. Chronic liver
failure is the most common indication for liver transplantation
(Graziadei 2016). Other important indications are acute liver
failure and hepatocellular carcinoma (Graziadei 2016). The median
survival aHer liver transplantation is in excess of 10 years (DuBy
2010; Schoening 2013; Kim 2018). The quality of life of people with
chronic liver disease may also improve aHer liver transplantation
(Yang 2014).
Approximately 7000 liver transplantations are performed in Europe
and 7800 liver transplantations in the USA each year (ELTR 2018;
Kim 2018). The majority of liver graHs are obtained from cadaveric
donors (Kim 2018; NHSBT 2018). Living donor liver transplantation
is associated with increased complications and retransplantation
and constitutes only a small proportion of liver transplantation
(Wan 2014). Recent data shows that approximately 13% of people in
the USA died on the waiting list at three years (Kim 2018), and 12%
of people on the UK waiting list died or became too unwell to be
transplanted at two years (NHSBT 2018), indicating organ shortage
necessitating an organ allocation policy. The model for end-stage
liver disease (MELD) score, which is calculated based on serum
bilirubin levels, creatinine levels, and international normalised
ratio (INR) for prothrombin time and first reported in 2001 (Kamath
2001), is the current method of selecting candidates and allocating
organs in the USA. A similar scoring system with the additional
parameter of sodium levels is used to calculate the UK model for
end-stage liver disease (UKELD), which is used by individual centres
for prioritising people for transplantation in the UK (Barber 2011).
Description of the intervention
As part of post-liver transplantation management,
immunosuppression (suppressing the host immunity) is given to
prevent graH rejections (Geissler 2009). GraH rejection can be
described as an immune response (either cell-mediated immunity
(mediated by cytotoxic T cells) or humoral immunity (antibody-
mediated immunity mediated by B lymphocytes)) of the body
against transplanted organ or tissues from a diBerent person
whose tissue antigens are not compatible with those of the
recipient (NCBI 2018). Human leukocyte antigen (HLA) typing and
matching is not used for organ allocation in liver transplantation
because there is no evidence of a diBerence in graH survival
between HLA-matched and HLA-mismatched liver transplantation
(Lan 2010). While transplanted liver graHs are less prone to
graH rejection than other organ transplants, immunosuppression
is routinely used for recipients of liver transplants (Geissler
2009). Various drugs have been used for immunosuppression,
including calcineurin inhibitors (cyclosporine A and tacrolimus),
antimetabolites (mycophenolate mofetil, mycophenolic acid, or
azathioprine), mTOR (mammalian target of rapamycin) inhibitors
(sirolimus, everolimus), corticosteroids (methylprednisolone), and
antibody-based therapies (thymoglobulin, antithymocyte globulin,
alemtuzumab, basiliximab, daclizumab) (Haddad 2006; Geissler
2009). These drugs can be classified into those that are used for
a short period during the beginning phase of immunosuppression
(initial immunosuppression or induction immunosuppression)
and those that are used for maintenance immunosuppression.
Induction immunosuppression oHen diBers from long-term
immunosuppression (maintenance immunosuppression) because
it is widely believed that graH rejections are more common during
the first few months aHer liver transplantation, although some
drugs, such as glucocorticosteroids, may be used for induction and
maintenance immunosuppression. Induction immunosuppression
is oHen used in addition to the same drugs used for maintenance
immunosuppression. The main purpose of these combinations
is to decrease the adverse events of the individual drugs (e.g.
nephrotoxicity of calcineurin inhibitors) by reduction in dosage and
to suppress immunity by multiple mechanisms (Geissler 2009).
Immunosuppression is associated with a variety of adverse events.
In addition to infections caused by immunosuppression, adverse
events include:
• corticosteroids: diabetes, hyperlipidaemia, osteoporosis, and
weight gain (BNF 2018);
• anti-thymocyte globulin: hypertension, nausea, shortness of
breath, fever, headache, anxiety, chills, increased potassium
levels in the blood, thrombocytopenia, and leukopaenia (FDA
2017);
• basiliximab: atrial flutter, cardiac arrest, cytokine release
syndrome, palpitations, severe hypersensitivity reactions (BNF
2018);
• daclizumab: elevation of liver enzymes, encephalitis, colitis,
depression (Drug and Therapeutics Bulletin 2018);
• alemtuzumab: arthralgia, back pain, cough, cytokine release
syndrome, tachycardia, leukopenia, thrombocytopenia (BNF
2018).
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)
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How the intervention might work
Corticosteroids inhibit arachidonic acid metabolism, antigen
presentation by dendritic cells, and interleukin-1 dependent
lymphocyte activation by decreasing interleukin-1 transcription
(Geissler 2009). Thymoglobulin and antithymocyte globulin are
antibodies against lymphocytes (Geissler 2009). Basiliximab and
daclizumab are interleukin-2 antibodies and so suppress T-cell
proliferation (Geissler 2009).
Why it is important to do this review
Research on the optimal immunosuppression regimen has been
identified as top research priorities by patients, carers, and
healthcare professionals involved in the treatment of liver
diseases in the UK (Gurusamy 2019). It is important to provide
optimal immunosuppression so that the transplanted liver and
the recipient can survive for the longest time possible and
with the least adverse events as possible. This is particularly
important given the shortage of donor organs. Several induction
immunosuppression regimens are available, and the optimal
regimen in terms of clinical eBectiveness or cost-eBectiveness
is unknown. There have been several Cochrane Reviews on
immunosuppression in liver transplantation (Haddad 2006;
Penninga 2012; Penninga 2014a; Penninga 2014b; Rodriguez-
Peralvarez 2017; Fairfield 2018). There is no previous network meta-
analysis on induction immunosuppressive regimens in people
undergoing liver transplantation. Network meta-analysis allows
for a combination of direct evidence and indirect evidence, and
the ranking of diBerent interventions in terms of the diBerent
outcomes (Salanti 2011; Salanti 2012). With this systematic
review and network meta-analysis, we aim to provide the
best level of evidence for the benefits and harms of diBerent
induction immunosuppressive regimens in people undergoing
liver transplantation. We have also presented results from direct
comparisons whenever possible, even if we performed the network
meta-analysis.
O B J E C T I V E S
To assess the comparative benefits and harms of diBerent
induction immunosuppressive regimens in adults undergoing liver
transplantation through a network meta-analysis and to generate
rankings of the diBerent induction immunosuppressive regimens
according to their safety and eBicacy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials (including cross-
over and cluster-randomised clinical trials) for this network meta-
analysis irrespective of language, publication status, or date of
publication. We excluded studies of other design because of the risk
of bias in such studies. Inclusion of indirect observational evidence
could weaken our network meta-analysis, but this could also be
viewed as a strength for assessing rare adverse events. It is well
established that exclusion of non-randomised studies increases
the focus on potential benefits and reduces the focus on the risks
of serious adverse events and those of any adverse events. We
planned a separate review on harms, but results from this review
(see EBects of interventions and Potential biases in the review
process) indicate this is not warranted.
Types of participants
We included randomised clinical trials with adult trial participants
undergoing liver transplantation, irrespective of the reason for liver
transplantation and whether it was primary transplantation or
retransplantation. We planned to exclude randomised clinical trials
in which participants had undergone multivisceral transplantation,
since the immunosuppressive regimens may have to be tailored for
the other organ; but did not find any such trials. We also excluded
randomised clinical trials that compared diBerent regimens in the
treatment of established graH rejections, as the main purpose of
routine induction immunosuppression is to prevent graH rejection.
Types of interventions
We included any of the following possible induction
immunosuppressive regimens aHer liver transplantation compared
with each other.
The following are the immunosuppressive regimens used alone or
in combination that we considered.





• No active intervention (no induction immunosuppression or
placebo for induction immunosuppression)
We treated each of the above interventions (regardless of the
gluocorticosteroid used, dose or duration, provided it was used for
induction immunosuppression) as diBerent nodes. We also treated
each combination of the above as a diBerent node. The reference
intervention was 'glucocorticosteroids'.
We did not include drugs that have been withdrawn from the
market, for example muromonab-CD3 (OKT3) or other interleukin-2
antibodies, since inclusion of these drugs in the analysis is unlikely
to guide future clinical practice.
We evaluated the plausibility of the network meta-analysis
transitivity assumption by looking at the inclusion and exclusion
criteria in the studies. Transitivity assumption is the assumption
that participants included in the diBerent trials undergoing
liver transplantation can be considered to be a part of a
multiarm randomised clinical trial and could potentially have
been randomised to any of the interventions by looking at the
inclusion and exclusion criteria in the studies (Salanti 2012). In
other words, any participant that meets the inclusion criteria
is, in principle, equally likely to be randomised to any of the
above eligible interventions. This necessitates that information on
potential eBect-modifiers, such as primary transplantation versus
retransplantation, and the reasons for liver transplantation should
be similar across trials.
Types of outcome measures
Primary outcomes
• All-cause mortality at maximal follow-up (time to death)
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• Time to graH loss (death or retransplantation) at maximal
follow-up
• Health-related quality of life as, defined in the included trials
using a validated scale such as the EQ-5D or 36-Item Short
Form Health Survey (SF-36) at maximal follow-up (EuroQol 2018;
Optum 2018)
• Serious adverse events (during or within 6 months aHer
cessation of intervention). We defined a serious adverse event
as any event that would increase mortality; is life-threatening;
requires hospitalisation; results in persistent or significant
disability; is a congenital anomaly/birth defect; or any important
medical event that might jeopardise the person or require
intervention to prevent it (ICH-GCP 1997). However, we used
the list provided by trial authors for serious adverse events (as
indicated in the protocol):
* proportion of trial participants with one or more serious
adverse event(s);
* number of serious adverse events per participant;
* proportion of participants with renal failure.
Secondary outcomes
• Any adverse events (during or within 6 months aHer cessation
of intervention). We defined an adverse event as any untoward
medical occurrence, not necessarily having a causal relationship
with the intervention, but resulting in a dose reduction or
discontinuation of intervention (any time aHer commencement
of the intervention) (ICH-GCP 1997). However, we used the list
provided by study authors for adverse events (as indicated in the
protocol):
* proportion of trial participants with one or more adverse
event(s);
* number of any adverse events per participant.
• Time to liver retransplantation (maximal follow-up)
• Time to acute graH rejection (maximal follow-up):
* any acute graH rejection;
* graH rejections requiring treatment (additional
immunosuppression or increase in dosage of one or more
components of the immunosuppression regimen).
Exploratory outcomes
• Costs (maximal follow-up). We planned to include costs related
to the drugs, treatment of induction immunosuppression-
related complications, and treatment-related monitoring.
We chose the outcomes based on their importance to patients in a
survey related to research priorities for people with liver diseases
(Gurusamy 2019).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid,
and Science Citation Index Expanded (Web of Science) from
inception to July 2019 for randomised clinical trials comparing two
or more of the above interventions. We did not apply any language
restrictions (Royle 2003). We searched for all possible comparisons
formed by the interventions of interest. To identify further
ongoing or completed trials, we also searched the US National
Institutes of Health Ongoing Trials Register ClinicalTrials.gov
(clinicaltrials.gov) and the World Health Organization International
Clinical Trials Registry Platform (apps.who.int/trialsearch/), which
searches various trial registers, including the ISRCTN registry and
ClinicalTrials.gov. We further searched the European Medicines
Agency (EMA) registry (www.ema.europa.eu/ema/) and the US
Food and Drug Administration (FDA) registry (www.fda.gov) for
randomised clinical trials. The search strategies are provided in
Appendix 1.
Searching other resources
We searched the references of the identified trials and existing
Cochrane Reviews on immunosuppression for liver transplantation
to identify additional trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KG and LB) independently screened the titles
and abstracts of studies identified by the search for potential
inclusion in the review. We sought full-text articles for any
references identified by at least one of the review authors for
potential inclusion and selected trials for inclusion based on the
full-text articles. We listed the excluded references and the reasons
for their exclusion in the 'Characteristics of excluded studies'
table. We also listed any ongoing trials identified primarily through
the search of the clinical trial registers for further follow-up. We
resolved any discrepancies through discussion.
Data extraction and management
Two review authors (KG and LB or JL) independently extracted the
data below onto a prepiloted MicrosoH Excel-based data extraction
form (aHer translation of non-English articles).
• Outcome data (for each outcome and for each intervention
group whenever applicable):
* number of participants randomised;
* number of participants included for the analysis;
* number of participants with events for binary outcomes,
mean and standard deviation for continuous outcomes,
number of events and mean follow-up period for count
outcomes, and number of participants with events and mean
follow-up period for time-to-event outcomes;
* natural logarithm of hazard ratio and its standard error, if
this was reported, rather than the number of participants
with events and mean follow-up period for time-to-event
outcomes;
* definition of outcomes or scale used, if appropriate.
• Data on potential eBect modifiers:
* participant characteristics, such as age, sex, comorbidities,
proportion of participants undergoing liver transplantation
for various reasons, and proportion of participants
undergoing retransplantation;
* details of the intervention and control (including dose,
frequency, and duration) such as additional intervention
for prevention of recurrence of disease that required
transplantation, e.g. antiviral preparations for participants
who had undergone liver transplantation for chronic
hepatitis C;
* length of follow-up;
* information related to 'Risk of bias' assessment (see below).
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• Other data:
* year and language of publication;
* country in which the participants were recruited;
* year(s) in which the trial was conducted;
* inclusion and exclusion criteria.
We collected outcomes at maximum follow-up, but also at short-
term (up to 3 months) and medium-term (from 3 months to 5 years)
follow-up, if these data were available.
We contacted the trial authors in the case of unclear or missing
information. We resolved any diBerences in opinion through
discussion.
Assessment of risk of bias in included studies
We followed the guidance in the Cochrane Handbook for Systematic
Reviews of Interventions to assess the risk of bias in included trials
(Higgins 2011). We specifically assessed the risk of bias in included
trials for the following domains using the methods below (Schulz
1995; Moher 1998; Kjaergard 2001; Wood 2008; Savović 2012a;
Savović 2012b; Savović 2018).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuBling
cards, and throwing dice are adequate if performed by an
independent person not otherwise involved in the study. In
general, we classified the risk of bias as low if the method
used for allocation concealment suggests that it was extremely
likely that the sequence was generated randomly (e.g. use of
interactive voice response system).
• Unclear risk of bias: the study authors did not specify the method
of sequence generation.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central
and independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe
the method used to conceal the allocation so that the
intervention allocations may have been foreseen before, or
during, enrolment.
• High risk of bias: it was likely that the investigators who assigned
the participants knew the allocation sequence. We excluded
such quasi-randomised studies.
Blinding of participants and personnel
• Low risk of bias: either blinding of participants and key study
personnel was ensured, and it was unlikely that the blinding
could have been broken; or rarely that there was no blinding
or incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding.
• Unclear risk of bias: either there was insuBicient information
to permit a judgement of low or high risk, or the trial did not
address this outcome.
• High risk of bias: either there was no blinding or incomplete
blinding, and the outcome was likely to be influenced by lack of
blinding; or blinding of key study participants and personnel was
attempted, but it was likely that the blinding could have been
broken, and the outcome was likely to be influenced by lack of
blinding.
Blinded outcome assessment
• Low risk of bias: either blinding of outcome assessment was
ensured, and it was unlikely that the blinding could have
been broken; or rarely that there was no blinding of outcome
assessment, but the review authors judged that the outcome
measurement was not likely to be influenced by lack of blinding.
• Unclear risk of bias: either there was insuBicient information
to permit a judgement of low or high risk, or the trial did not
address this outcome.
• High risk of bias: either there was no blinding of outcome
assessment, and the outcome measurement was likely to be
influenced by lack of blinding; or there was blinding of outcome
assessment, but it was likely that the blinding could have
been broken, and the outcome measurement was likely to be
influenced by lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make treatment
eBects depart from plausible values. The study used suBicient
methods, such as multiple imputation, to handle missing data.
• Unclear risk of bias: there was insuBicient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias on the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: at least one of the outcomes related to the main
reason for treatment of people with immunosuppression,
namely, all-cause mortality or graH loss at maximal follow-up
along with intervention-related adverse events. If the original
trial protocol was available, the outcomes should have been
those called for in that protocol. If the trial protocol was obtained
from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought
should have been those enumerated in the original protocol if
the trial protocol was registered before or at the time that the
trial was begun. If the trial protocol was registered aHer the trial
had begun, those outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined or clinically relevant and
reasonably expected outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically relevant
and reasonably expected outcomes were not reported, despite
the fact that data on these outcomes should have been available
and even recorded.
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Other bias
• Low risk of bias: the trial appeared to be free of other
components that could put it at risk of bias (e.g. inappropriate
control or dose or administration of control, baseline
diBerences, early stopping).
• Unclear risk of bias: the trial may or may not have been free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that could
put it at risk of bias (e.g. baseline diBerences, early stopping).
We considered a trial to be at low risk of bias if we assessed
the trial to be at low risk of bias across all listed 'Risk of bias'
domains; otherwise, we considered trials to be at high risk of
bias. At the outcome level, we classified an outcome to be at
low risk of bias if the allocation sequence generation; allocation
concealment; blinding of participants, healthcare professionals,
and outcome assessors; incomplete outcome data; and selective
outcome reporting (at the outcome level) were at low risk of bias
for objective and subjective outcomes (Savović 2018).
Measures of treatment eGect
Relative treatment eects
For dichotomous variables (e.g. proportion of participants with
serious adverse events or any adverse events), we calculated
the odds ratio (OR) with 95% credible interval (CrI) (or Bayesian
confidence interval) (Severini 1993). For continuous variables (e.g.
health-related quality of life reported on the same scale), we
calculated the mean diBerence (MD) with 95% Crl. We used
standardised mean diBerence (SMD) values with 95% Crl for health-
related quality of life if the included trials used diBerent scales.
If we calculated the SMD, we planned to convert it to a common
scale, for example, EQ5D or SF-36 (using the standard deviation
of the common scale) for the purpose of interpretation. For count
outcomes (e.g. number of serious adverse events or number of any
adverse events), we calculated the rate ratio (RaR) with 95% Crl.
This assumes that the events are independent of each other, i.e. if a
person has had an event, they are not at an increased risk of further
outcomes, which is the assumption in Poisson likelihood. For time-
to-event data (e.g. all-cause mortality at maximal follow-up), we
calculated hazard ratio (HR) with 95% Crl. If the CrI overlaps 0 for
diBerences and 1 for ratios, this indicates that there is no evidence
of diBerence (i.e. no statistically significant diBerence).
Relative ranking
We estimated the ranking probabilities for all interventions of
being at each possible rank for each intervention for each of the
primary and secondary outcomes. We obtained the surface under
the cumulative ranking curve (SUCRA) (cumulative probability),
rankogram, and relative ranking table with CrI for the ranking
probabilities (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis was the participant undergoing liver
transplantation according to the intervention group to which the
participant was randomly assigned.
Cluster-randomised clinical trials
If we identified any cluster-randomised clinical trials, we planned
to include cluster-randomised clinical trials, provided that the
eBect estimate adjusted for cluster correlation was available or if
there was suBicient information available to calculate the design
eBect (which would allow us to take clustering into account).
We also planned to assess additional 'Risk of bias' domains for
cluster-randomised trials according to the guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Cross-over randomised clinical trials
If we identified any cross-over randomised clinical trials, we
planned to include the outcomes aHer the period of first
intervention, because the included treatments can have residual
eBects.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the
inclusion criteria. The codes for analysis we used accounted for the
correlation between the eBect sizes from studies with more than
two groups.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992); otherwise, we used the data available to us. When
intention-to-treat analysis was not used and the data were not
missing at random (for example, treatment was withdrawn due to
adverse events or duration of treatment was shortened because
of lack of response and such participants were excluded from
analysis), it could lead to biased results; therefore, we conducted
best-worst case scenario analysis (assuming a good outcome in
the intervention group and bad outcome in the control group)
and worst-best case scenario analysis (assuming a bad outcome
in the intervention group and good outcome in the control group)
as sensitivity analyses whenever possible for binary and time-to-
event outcomes, where binomial likelihood was used.
For continuous outcomes, we planned to impute the standard
deviation from P values, according to guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the data were likely to be normally distributed, we planned
to use the median for meta-analysis when the mean was not
available; otherwise, we planned to simply provide a median and
interquartile range of the diBerence in medians. If it was not
possible to calculate the standard deviation from the P value or the
confidence intervals, we planned to impute the standard deviation
using the largest standard deviation in other trials for that outcome.
This form of imputation can decrease the weight of the study for
calculation of mean diBerences and may bias the eBect estimate to
no eBect for calculation of SMDs (Higgins 2011).
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by carefully
examining the characteristics and design of included trials.
We planned to assess the presence of clinical heterogeneity
by comparing eBect estimates (see Subgroup analysis and
investigation of heterogeneity) in trial reports of diBerent reasons
for liver transplantation, and primary liver transplantation versus
retransplantation. DiBerent study designs and risk of bias could
contribute to methodological heterogeneity.
We assessed statistical heterogeneity by comparing the results
of the fixed-eBect model meta-analysis and the random-eBects
model meta-analysis, between-study standard deviation (Tau2 and
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comparing this with values reported in a study of the distribution
of between-study heterogeneity estimates) (Turner 2012), and by
calculating I2 (Jackson 2014), using Stata 15. If we identified
substantial clinical, methodological, or statistical heterogeneity,
we planned to explore and address the heterogeneity in
subgroup analysis (see Subgroup analysis and investigation of
heterogeneity).
Assessment of transitivity across treatment comparisons
We assessed the transitivity assumption by comparing
the distribution of the potential eBect modifiers (clinical:
primary transplantation or retransplantation, reasons for
liver transplantation; methodological: risk of bias, year of
randomisation, duration of follow-up) across the diBerent pairwise
comparisons.
Assessment of reporting biases
For the network meta-analysis, we planned to perform a
comparison-adjusted funnel plot. However, to interpret a
comparison-adjusted funnel plot, it is necessary to rank the studies
in a meaningful way as asymmetry may be due to small sample
sizes in newer studies (comparing newer treatments with older
treatments) or higher risk of bias in older studies (comparing
older treatments with placebo) (Chaimani 2012). As there was no
meaningful way in which to rank these studies (i.e. there was no
specific change in the risk of bias in the studies, sample size, or the
control group used over time), we judged the reporting bias by the
completeness of the search (Chaimani 2012). We also considered
lack of reporting of outcomes as a form of reporting bias.
Data synthesis
Methods for indirect and mixed comparisons
We conducted network meta-analyses to compare multiple
interventions simultaneously for each of the primary and
secondary outcomes. Network meta-analysis combines direct
evidence within trials and indirect evidence across trials (Mills
2012). We obtained a network plot to ensure that the trials
are connected by interventions using Stata 15 (Chaimani 2013).
We excluded any trials that are not connected to the network
from the network meta-analysis, and we reported only the direct
pairwise meta-analysis for such comparisons. We summarised
the population and methodological characteristics of the trials
included in the network meta-analysis in a table based on pairwise
comparisons. We conducted a Bayesian network meta-analysis
using the Markov chain Monte Carlo method in OpenBUGS 3.2.3,
according to guidance from the National Institute for Health and
Care Excellence (NICE) Decision Support Unit (DSU) documents
(Dias 2016). We modelled the treatment contrast (i.e. log odds
ratio for binary outcomes, MD or SMD for continuous outcomes,
log rate ratio for count outcomes, and log hazard ratio for
time-to-event outcomes) for any two interventions ('functional
parameters') as a function of comparisons between each individual
intervention and the reference group ('basic parameters'), using
appropriate likelihood functions and links (Lu 2006a). We used
binomial likelihood and logit link for binary outcomes, Poisson
likelihood and log link for count outcomes, binomial likelihood
and complementary log-log link (a semiparametric model which
excludes censored individuals from the denominator of ‘at risk’
individuals at the point when they are censored) for time-to-event
outcomes, and normal likelihood and identity link for continuous
outcomes. We used 'glucocorticosteroids' as the reference group
across the networks. We used a fixed-eBect model and random-
eBects model for the network meta-analysis. We reported both
models for comparison with the reference group in a forest plot
when the results were diBerent between the models. For each
pairwise comparison in a table, we reported the fixed-eBect model
if the two models report similar results; otherwise, we reported
the more conservative model, i.e. usually using the random-eBects
model in the absence of ‘small-study’ bias.
We used a hierarchical Bayesian model using three diBerent sets
of initial values to start the simulation-based parameter estimation
to assist with the assessment of convergence, employing codes
provided by the NICE DSU (Dias 2016). We used a normal
distribution with large variance (10,000) for treatment eBect priors
(vague or flat priors) centred at no eBect. For the random-
eBects model, we used a prior distributed uniformly (limits: 0
to 5) for the between-trial standard deviation parameter and
assumed this variability would be the same across treatment
comparisons (Dias 2016). We used a 'burn-in' of 30,000 iterations,
checked for convergence (of eBect estimates and between-study
heterogeneity) visually (i.e. checked whether the values in diBerent
chains mix very well by visualisation), and ran the models for
another 10,000 iterations to obtain eBect estimates. If we did
not obtain convergence, we increased the number of iterations
for the 'burn-in' and used the 'thin' and 'over relax' functions to
decrease the autocorrelation. If we still did not obtain convergence,
we planned to use alternate initial values and priors employing
methods suggested by Van Valkenhoef 2012. We estimated the
probability that each intervention ranks at each of the possible
positions using the NICE DSU codes (Dias 2016).
Assessment of inconsistency
We assessed inconsistency (statistical evidence of the violation
of transitivity assumption) by fitting both an inconsistency model
and a consistency model. We used inconsistency models employed
in the NICE DSU manual, as we used a common between-study
standard deviation (Dias 2014). In addition, we used design-by-
treatment full interaction model and inconsistency factor (IF) plots
to assess inconsistency when applicable (Higgins 2012; Chaimani
2013). We used Stata 15 to create IF plots. In the presence of
inconsistency, we planned to assess whether the inconsistency
was due to clinical or methodological heterogeneity by performing
separate analyses for each of the diBerent subgroups mentioned in
the Subgroup analysis and investigation of heterogeneity section.
If there was evidence of inconsistency, we planned to identify areas
in the network where substantial inconsistency might be present
in terms of clinical and methodological diversities between trials,
and, when appropriate, limited network meta-analysis to a more
compatible subset of trials.
Direct comparison
We performed the direct comparisons using the same codes and the
same technical details.
Subgroup analysis and investigation of heterogeneity
We planned to assess the diBerences in the eBect estimates
between the following subgroups, and investigate heterogeneity
and inconsistency using meta-regression with the help of the codes
provided in the NICE DSU guidance (Dias 2012a), if we included a
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suBicient number of trials (when there were at least 2 trials in at
least 2 of the subgroups) and when the interaction term could be
calculated. We planned to use the following trial-level covariates for
meta-regression.
• Trials at low risk of bias compared to trials at high risk of bias
• DiBerent reasons for undergoing liver transplantation
• Primary liver transplantation compared to retransplantation
• Additional immunosuppression drugs received
• Maintenance immunosuppression altered at the time of
withdrawal of induction immunosuppression versus no
alteration in maintenance immunosuppression at the time of
withdrawal of induction immunosuppression
• Based on the period of follow-up (short-term: up to 3 months;
medium-term: more than 3 months to 5 years; long-term: more
than 5 years)
• Based on the definition used by authors for serious adverse
events and any adverse events (ICH-GCP 1997 versus other
definitions).
We planned to calculate a single common interaction term
(which assumes each relative treatment eBect versus a common
comparator treatment (glucocorticiosteroids) is impacted in the
same way by the covariate in question) when applicable (Dias
2012a). If the 95% Crl of the interaction term does not overlap
zero, we would have considered this statistically significant
heterogeneity.
Sensitivity analysis
If there were post-randomisation dropouts, we reanalysed the
results using the best-worst case scenario and worst-best case
scenario as sensitivity analyses whenever possible. We also
planned to perform a sensitivity analysis excluding the trials in
which mean or standard deviation (or both) were imputed, and
we planned to use the median standard deviation in the trials to
impute missing standard deviations.
Presentation of results
We followed the PRISMA-NMA statement while reporting (Hutton
2015). We presented the eBect estimates with 95% CrI for each
pairwise comparison calculated from the direct comparisons and
network meta-analysis. We originally planned to present the
cumulative probability of the treatment ranks (i.e. the probability
that the intervention is within the top 2, the probability that the
intervention is within the top 3 etc.), but we did not present these
because of the sparse data which can lead to misinterpretation of
results due to large uncertainty in the rankings (the CrI was 0 to 1
for all the ranks) in graphs (SUCRA) (Salanti 2011). We plotted the
probability that each intervention was best, second best, third best,
etc. for each of the diBerent outcomes (rankograms), which are
generally considered more informative (Salanti 2011; Dias 2012b),
but we did not present these because of the sparse data which can
lead to misinterpretation of results due to large uncertainty in the
rankings (the CrI was 0 to 1 for all the ranks). We uploaded all the raw
data and the codes used for analysis in The European Organization
for Nuclear Research open source database (Zenodo): the link is:
doi.org/10.5281/zenodo.3524994.
Grading of evidence
We presented 'Summary of findings' tables for all the primary
and secondary outcomes (see Primary outcomes; Secondary
outcomes). We followed the approach suggested by Yepes-Nunez
and colleagues (Yepes-Nunez 2019). First, we calculated the direct
and indirect eBect estimates (when possible) and 95% Crl using
the node-splitting approach (Dias 2010), that is calculating the
direct estimate for each comparison by including only trials in
which there was direct comparison of interventions and the
indirect estimate for each comparison by excluding the trials
in which there was direct comparison of interventions (and
ensuring a connected network). Next, we rated the quality of direct
and indirect eBect estimates using GRADE methodology which
takes into account the risk of bias, inconsistency (heterogeneity),
directness of evidence (including incoherence, the term used
in GRADE methodology for inconsistency in network meta-
analysis), imprecision, and publication bias (Guyatt 2011). We
then presented the relative and absolute estimates of the meta-
analysis with the best certainty of evidence and used it to
interpret the findings (Yepes-Nunez 2019). We also presented
the 'Summary of findings' tables in a second format presenting
all the outcomes for selected interventions (Yepes-Nunez
2019): we selected the four interventions (glucocorticosteroids,
basiliximab plus glucocorticosteroids, anti-thymocyte globulin
plus glucocorticosteroids, and basiliximab alone) which were
compared in the most trials (Table 1).
Recommendations for future research
We provided recommendations for future research regarding the
population, intervention, control, outcomes, period of follow-up,
and study design, based on the uncertainties that we identified
from the existing research.
R E S U L T S
Description of studies
Results of the search
We identified 3109 references through electronic searches of
CENTRAL (Wiley) (n = 474), MEDLINE Ovid (n = 1149), Embase Ovid (n
= 830), Science Citation Index expanded (n = 384), ClinicalTrials.gov
(n = 84) and World Health Organization (WHO) Trials register (n
= 80), and identified two references by searching the European
Medicines Agency (EMA) and 106 references by searching the Food
and Drug Administration (FDA) registries. AHer removing duplicate
references, there were 2463 references. We excluded 2371 clearly
irrelevant references through reading titles and abstracts. We
retrieved a total of 92 full-text references for further assessment in
detail. We excluded 42 references (26 studies) for the reasons stated
in the Characteristics of excluded studies tables. There were two
ongoing trials without interim data, and two studies are awaiting
classification because of lack of full text. Thus, we included a total
of 25 trials described in 46 references (Characteristics of included
studies tables). The reference flow is shown in Figure 3.
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Figure 3.   Study flow diagram.
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Included studies
We included 25 trials (Tisone 1999; Belli 2001; Washburn 2001;
Neuhaus 2002; Eason 2003; Filipponi 2004; Bogetti 2005; Boillot
2005; Yoshida 2005; Llado 2006; Lu 2006a; NCT 2006a; Kato 2007;
Schmeding 2007; Lupo 2008; Washburn 2008; Boillot 2009; Benitez
2010; Calmus 2010; Klintmalm 2011; Neumann 2012; Ramirez
2013; Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014; Kathirvel
2018). A total of 3271 participants were randomised to diBerent
interventions. The number of participants ranged from 19 to
708. A total of 3017 participants from 23 trials were included in
one or more outcomes (Tisone 1999; Belli 2001; Washburn 2001;
Neuhaus 2002; Eason 2003; Bogetti 2005; Boillot 2005; Yoshida
2005; Llado 2006; Lu 2006; Kato 2007; Schmeding 2007; Lupo
2008; Washburn 2008; Boillot 2009; Benitez 2010; Calmus 2010;
Klintmalm 2011; Neumann 2012; Ramirez 2013; Garcia-Saenz-De-
Sicilia 2014; Klintmalm 2014; Kathirvel 2018). The mean or median
age in the trials ranged from 48 to 62 years in the trials that
reported this information (Tisone 1999; Washburn 2001; Neuhaus
2002; Filipponi 2004; Bogetti 2005; Boillot 2005; Yoshida 2005; Llado
2006; Kato 2007; Schmeding 2007; Lupo 2008; Boillot 2009; Benitez
2010; Calmus 2010; Klintmalm 2011; Neumann 2012; Ramirez 2013;
Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014; Kathirvel 2018). The
proportion of females ranged from 12.8% to 45.5% in the trials that
reported this information (Tisone 1999; Washburn 2001; Neuhaus
2002; Filipponi 2004; Bogetti 2005; Boillot 2005; Yoshida 2005; Llado
2006; Kato 2007; Schmeding 2007; Lupo 2008; Boillot 2009; Benitez
2010; Calmus 2010; Klintmalm 2011; Neumann 2012; Ramirez
2013; Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014). The follow-
up period in the trials ranged from three to 76 months in the
trials. Two trials had short-term follow-up (up to 3 months) (Bogetti
2005; Boillot 2005); 20 trials had medium-term follow-up (more
than 3 months to 5 years) (Tisone 1999; Belli 2001; Washburn
2001; Neuhaus 2002; Eason 2003; Filipponi 2004; Yoshida 2005;
Llado 2006; Lu 2006; Kato 2007; Lupo 2008; Washburn 2008; Boillot
2009; Benitez 2010; Calmus 2010; Klintmalm 2011; Neumann 2012;
Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014; Kathirvel 2018); two
trials had long-term follow-up (more than 5 years) (Schmeding
2007; Ramirez 2013). The follow-up in one trial was not reported
(NCT 2006b). The median follow-up among the trials was 12
months.
Eighteen trials reported the proportion of participants who had
primary transplantation: in all 18 trials, all the participants
underwent primary transplantation (Washburn 2001; Neuhaus
2002; Filipponi 2004; Boillot 2005; Yoshida 2005; Llado 2006;
Kato 2007; Lupo 2008; Washburn 2008; Boillot 2009; Benitez
2010; Calmus 2010; Klintmalm 2011; Neumann 2012; Ramirez
2013; Klintmalm 2014; Garcia-Saenz-De-Sicilia 2014; Kathirvel
2018). Fourteen trials reported the proportion of participants
who had hepatocellular carcinoma (HCC) as the major indication
for transplantation: in seven trials, none of the participants
had HCC as the major indication for transplantation (Neuhaus
2002; Filipponi 2004; Bogetti 2005; Kato 2007; Klintmalm 2011;
Neumann 2012; Garcia-Saenz-De-Sicilia 2014); in the remaining
seven trials, the proportion of participants who had HCC as
the major indication for transplantation ranged from 13.1%
to 52.5% (Boillot 2005; Llado 2006; Schmeding 2007; Lupo
2008; Benitez 2010; Calmus 2010; Ramirez 2013). Nineteen trials
reported the proportion of participants who had other reasons
as the major indication for transplantations: in six trials, none
of the participants had other reasons as the major indication
for transplantations (Filipponi 2004; Bogetti 2005; Kato 2007;
Klintmalm 2011; Neumann 2012; Garcia-Saenz-De-Sicilia 2014); in
the remaining 13 trials, the proportion of participants who had
other reasons as the major indication for transplantations ranged
from 7.4% to 32.4% (Tisone 1999; Washburn 2001; Neuhaus 2002;
Eason 2003; Boillot 2005; Yoshida 2005; Llado 2006; Schmeding
2007; Lupo 2008; Boillot 2009; Benitez 2010; Calmus 2010; Ramirez
2013). Seventeen trials reported the proportion of participants
who had alcohol-related cirrhosis as the major indication for
transplantation: in five trials, none of the participants had alcohol-
related cirrhosis as the major indication for transplantation
(Filipponi 2004; Kato 2007; Klintmalm 2011; Neumann 2012; Garcia-
Saenz-De-Sicilia 2014); in the remaining 12 trials, the proportion
of participants who had alcohol-related cirrhosis as the major
indication for transplantation ranged from 10.1% to 67.6% (Tisone
1999; Washburn 2001; Neuhaus 2002; Eason 2003; Bogetti 2005;
Yoshida 2005; Llado 2006; Schmeding 2007; Boillot 2009; Benitez
2010; Calmus 2010; Ramirez 2013). Eighteen trials reported the
proportion of participants who had viral-related cirrhosis as
the major indication for transplantation: in five trials, all the
participants had viral-related cirrhosis as the major indication
for transplantation (Filipponi 2004; Kato 2007; Klintmalm 2011;
Neumann 2012; Garcia-Saenz-De-Sicilia 2014); in the remaining
13 trials, the proportion of participants who had viral-related
cirrhosis as the major indication for transplantation ranged from
5.4% to 85.1% (Tisone 1999; Washburn 2001; Neuhaus 2002; Eason
2003; Bogetti 2005; Yoshida 2005; Llado 2006; Schmeding 2007;
Lupo 2008; Boillot 2009; Benitez 2010; Calmus 2010; Ramirez
2013). Sixteen trials reported the proportion of participants who
had autoimmune disease-related cirrhosis as the main reason
for transplantation: in eight trials, none of the participants had
autoimmune disease-related cirrhosis as the major indication for
transplantation (Washburn 2001; Filipponi 2004; Llado 2006; Kato
2007; Benitez 2010; Klintmalm 2011; Neumann 2012; Garcia-Saenz-
De-Sicilia 2014); in the remaining eight trials, the proportion of
participants who had autoimmune disease-related cirrhosis as the
major indication for transplantation ranged from 5.0% to 23.0%
(Neuhaus 2002; Eason 2003; Bogetti 2005; Boillot 2005; Yoshida
2005; Schmeding 2007; Boillot 2009; Ramirez 2013). In 21 trials, the
drugs used for maintenance immunosuppression drugs were the
same as that accompanying the induction immunosuppression.
In the remaining four trials, the maintenance immunosuppression
was altered: this involved dropping azathioprine or mycophenolate
from the drug combination (Belli 2001; Eason 2003; Calmus 2010;
Garcia-Saenz-De-Sicilia 2014).
A total of eight interventions were compared in these trials. The
important characteristics, potential eBect modifiers, and follow-up
in each trial is reported in Table 1. Overall, there do not seem to be
any systematic diBerences between the comparisons.
Funding: the source of funding for 14 trials was drug companies
who would benefit from the results of the study (Washburn 2001;
Neuhaus 2002; Eason 2003; Filipponi 2004; Boillot 2005; Llado 2006;
NCT 2006b; Kato 2007; Benitez 2010; Calmus 2010; Klintmalm 2011;
Neumann 2012; Ramirez 2013; Klintmalm 2014); two trials were
funded by neutral organisations who have no vested interests in
the results of the study (Lu 2006; Garcia-Saenz-De-Sicilia 2014); the
source of funding for the remaining nine trials was unclear (Tisone
1999; Belli 2001; Bogetti 2005; Yoshida 2005; Schmeding 2007; Lupo
2008; Washburn 2008; Boillot 2009; Kathirvel 2018).
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Excluded studies
The reasons for exclusion is provided in the Characteristics of
excluded studies tables. The summary of reasons for exclusion are
as follows.
• A proportion of participants in the groups compared received
one of the interventions of interest for this review which was not
decided at random (Pelletier 2005; Neuberger 2009; Trunecka
2015).
• Both groups received glucocorticosteroids; the duration of
treatment or type of glucocorticosteroids in the groups was
diBerent between the groups (Margarit 2005; Lerut 2008; Saliba
2016; NCT 2017).
• Not a comparison of interest for this review (Reding 1993; Farges
1994; Ismail 1995; Glanemann 1998; Klupp 1998; Langrehr 1998;
Samuel 1998; Jain 2002; Serrano 2002; NCT 2007; Iesari 2018).
• Not a randomised clinical trial (Tzakis 2004; Liu 2013).
• The interventions in the groups compared were not clear (NCT
2005; NCT 2006b; Turner 2006; EUCTR 2009; ISRCTN 2010).
• The other immunosuppressive drugs were diBerent in the two
groups, i.e. the co-interventions were diBerent in the two groups
(Russell 2016).
Risk of bias in included studies
The risk of bias is summarised in Figure 4, Figure 5, and in Table 2.
Only one trial was at low risk of bias in all the domains (Neuhaus
2002). All the remaining trials were at unclear or high risk of bias in
at least one of the domains and were considered to be at high risk
of bias.
 
Figure 4.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 5.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 5.   (Continued)
 
Allocation
Ten trials were at low risk of sequence generation bias (Tisone 1999;
Neuhaus 2002; Filipponi 2004; Lupo 2008; Boillot 2009; Benitez
2010; Calmus 2010; Neumann 2012; Ramirez 2013; Klintmalm
2014); the remaining 15 trials, which did not provide suBicient
information, were at unclear risk of sequence generation bias
(Belli 2001; Washburn 2001; Eason 2003; Bogetti 2005; Boillot
2005; Yoshida 2005; Llado 2006; Lu 2006; NCT 2006b; Kato 2007;
Schmeding 2007; Washburn 2008; Klintmalm 2011; Garcia-Saenz-
De-Sicilia 2014; Kathirvel 2018).
Nine trials were at low risk of allocation concealment bias
(Neuhaus 2002; Filipponi 2004; Llado 2006; Lupo 2008; Benitez
2010; Calmus 2010; Neumann 2012; Ramirez 2013; Klintmalm
2014); the remaining 16 trials, which did not provide suBicient
information, were at unclear risk of allocation concealment bias
(Tisone 1999; Belli 2001; Washburn 2001; Eason 2003; Bogetti
2005; Boillot 2005; Yoshida 2005; Lu 2006; NCT 2006b; Kato 2007;
Schmeding 2007; Washburn 2008; Boillot 2009; Klintmalm 2011;
Garcia-Saenz-De-Sicilia 2014; Kathirvel 2018).
Blinding
Three trials were at low risk of blinding of participants and
healthcare provider bias (Neuhaus 2002; Filipponi 2004; Klintmalm
2014); nine trials, which did not provide suBicient information,
were at unclear risk of blinding of participants and healthcare
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provider bias (Belli 2001; Eason 2003; Bogetti 2005; Yoshida 2005;
Lu 2006; Kato 2007; Schmeding 2007; Lupo 2008; Kathirvel 2018);
the remaining 13 trials were at high risk of blinding of participants
and healthcare provider bias (Tisone 1999; Washburn 2001; Boillot
2005; Llado 2006; NCT 2006b; Washburn 2008; Boillot 2009; Benitez
2010; Calmus 2010; Klintmalm 2011; Neumann 2012; Ramirez 2013;
Garcia-Saenz-De-Sicilia 2014). The risk of outcome bias due to lack
of outcome assessor blinding was the same in the trials.
Incomplete outcome data
Eleven trials were at low risk of incomplete outcome data bias
(Tisone 1999; Neuhaus 2002; Eason 2003; Filipponi 2004; Yoshida
2005; Lu 2006; Lupo 2008; Boillot 2009; Benitez 2010; Ramirez
2013; Kathirvel 2018); 12 trials were at unclear risk of incomplete
outcome data bias (Belli 2001; Washburn 2001; Bogetti 2005; Boillot
2005; Llado 2006; NCT 2006b; Schmeding 2007; Washburn 2008;
Klintmalm 2011; Neumann 2012; Garcia-Saenz-De-Sicilia 2014;
Klintmalm 2014), because it was not clear whether there were
post-randomisation dropouts or whether the post-randomisation
dropouts were related to the outcomes (if there were post-
randomisation dropouts); the remaining two trials were at high
risk of incomplete outcome data bias (Kato 2007; Calmus 2010),
as the post-randomisation dropouts were probably related to the
intervention and outcomes.
Selective reporting
Ten trials were at low risk of selective outcome reporting bias
(Neuhaus 2002; Boillot 2005; Yoshida 2005; Llado 2006; Lupo
2008; Boillot 2009; Benitez 2010; Calmus 2010; Neumann 2012;
Klintmalm 2014), as the important clinical outcomes expected to
be reported in such trials were reported; the remaining 15 trials
were at high risk of selective outcome reporting bias (Tisone 1999;
Belli 2001; Washburn 2001; Eason 2003; Filipponi 2004; Bogetti
2005; Lu 2006; NCT 2006b; Kato 2007; Schmeding 2007; Washburn
2008; Klintmalm 2011; Ramirez 2013; Garcia-Saenz-De-Sicilia 2014;
Kathirvel 2018), as the trials did not report the reasonably expected
clinical outcomes (none of the trials had a pre-published protocol
available).
Other potential sources of bias
It was not possible to assess the other risk of bias in NCT 2006a;
six trials were at high risk of other bias: the dose or duration
of other immunosuppressive drugs were diBerent between the
groups in four trials (Yoshida 2005; Benitez 2010; Ramirez
2013; Klintmalm 2014), the maintenance immunosuppression was
diBerent between the groups in one trial (Washburn 2001), or only
as-treated analysis was reported in one trial (Filipponi 2004); all the
remaining trials were at low risk of other bias.
EGects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2
The network plots (where relevant) are available in Figure 1
and Figure 2. The inconsistency factor plots (where relevant) are
available in Figure 6. The diBerences in the fixed-eBect versus
random-eBects models (where relevant) are available in Figure
7. The model fit is available in Table 3. The eBect estimates are
available in Table 4.
 
Figure 6.   Inconsistency factor plots showing the inconsistency factors for the outcomes with direct and indirect
evidence available for one or more comparisons. There was no evidence of inconsistency except for gra4 failure. A
high resolution image is available at: http://doi.org/10.5281/zenodo.3524994. Abbreviations
ATG = anti-thymocyte globulin
Steroids = glucocorticosteroids
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NoActiveIntervention = no active intervention (i.e. only maintenance immunosuppression)
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Figure 6.   (Continued)
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Figure 7.   Forest plots showing the outcomes for which the random-eGects model had better model fit or was
diGerent from the fixed-eGect model. The more conservative random-eGects model was used in these situations
(i.e. when random-eGects model had better model fit or was diGerent from the fixed-eGect model). Abbreviations
ATG = anti-thymocyte globulin
Steroids = glucocorticosteroids
No active intervention = only maintenance immunosuppression
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)
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The 95% credible intervals (CrIs) of the probability ranks were
wide and included 0 and 1 for all the comparisons. This was
probably because of the sparse data from mostly small trials giving
heterogeneous results. Therefore, we did not present the ranking
probabilities (in a table), rankograms, and SUCRA plots as we
considered that presenting this information would be unhelpful
and potentially misleading and ignore the diBerences in systematic
errors in the trials.
The summary of findings is available in the Summary of findings for
the main comparison and Summary of findings 2. The certainty of
evidence was very low for all the comparisons. This was because all
but two trials were at unclear or high risk of bias for one or more risk
of bias domains at the outcome level (downgraded one level), the
sample size was small (downgraded one level), and the wide CrIs
overlapping significant clinical eBect and no eBect (downgraded
one level) (Neuhaus 2002; Filipponi 2004).
Mortality at maximal follow-up
Twnenty-one trials (2928 participants) reported mortality at
maximal follow-up (Tisone 1999; Washburn 2001; Neuhaus 2002;
Eason 2003; Bogetti 2005; Boillot 2005; Yoshida 2005; Llado 2006;
Lu 2006; Schmeding 2007; Lupo 2008; Washburn 2008; Boillot
2009; Benitez 2010; Calmus 2010; Klintmalm 2011; Neumann
2012; Ramirez 2013; Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014;
Kathirvel 2018). A total of eight treatments were compared in these
trials. All the trials were connected to the network.##; ##
We used the random-eBects model because it was more
conservative, even though the model fit was similar to the fixed-
eBect model. The between-study variance was 0.06 (95% CrI 0.00 to
0.56). There was no evidence of inconsistency according to model
fit and inconsistency factor. Despite diBerent measures, we were
unable to obtain convergence for the model fit procedure of the
design-by-treatment model.
There was no evidence of diBerences in any of the direct
comparisons (i.e. there was no statistically significant diBerence in
any of the comparisons; very low-certainty evidence) (Summary of
findings 2; Table 4).
In the network meta-analysis, the following comparisons were
statistically significant.
• Basiliximab versus glucocorticosteroids: hazard ratio (HR) 0.53,
95% CrI 0.31 to 0.93 (low-certainty evidence); direct comparison
HR 0.50, 95% CrI 0.02 to 12.55.
• Basiliximab versus anti-thymocyte globulin plus
glucocorticosteroids: HR 0.31, 95% CrI 0.11 to 0.89 (low-certainty
evidence); no direct comparison.
• Daclizumab plus glucocorticosteroids versus basiliximab: HR
2.53, 95% CrI 1.16 to 5.66 (low-certainty evidence); basiliximab
versus daclizumab plus glucocorticosteroids: HR 0.40, 95% CrI
0.40 to 0.86; no direct comparison.
i.e. basiliximab appears to have lower mortality than
glucocorticosteroids alone, anti-thymocyte globulin plus
glucocorticosteroids, and daclizumab plus glucocorticosteroids
(low-certainty evidence).
There were no subgroup diBerences. The sensitivity analysis
indicated that the diBerent scenarios (best-worst and worst-
best scenarios) for imputing missing data indicated a diBerent
interpretation of results; therefore, the results have to be
interpreted with caution. However, the above three comparisons in
which there was evidence of diBerence continued to be statistically
significant.
Gra4 failure at maximal follow-up
Sixteen trials (2505 participants) reported graH failure at maximal
follow-up (Tisone 1999; Washburn 2001; Neuhaus 2002; Eason
2003; Bogetti 2005; Boillot 2005; Llado 2006; Schmeding 2007;
Lupo 2008; Boillot 2009; Benitez 2010; Calmus 2010; Klintmalm
2011; Neumann 2012; Ramirez 2013; Klintmalm 2014). A total of
eight treatments were compared in these trials. All the trials were
connected to the network.
We used the random-eBects model because of a better model
fit than the fixed-eBect model, and it was the more conservative
model. The between-study variance was 0.29 (95% CrI 0.04 to 1.71).
There was evidence of inconsistency according to the inconsistency
factors, but not by model fit; therefore, there is uncertainty in
the validity of network meta-analysis results: direct comparisons
are more reliable. Despite diBerent measures, we were unable to
obtain convergence for the model fit procedure of the design-by-
treatment model.
The following direct comparison was statistically significant
• Basiliximab versus glucocorticosteroids: HR 0.44, 95% CrI
0.28 to 0.70; 1 trial, 47 participants; low-certainty evidence
(i.e. decreased graH failure with basiliximab compared to
glucocorticosteroids); eBect estimate in network meta-analysis
was: HR 0.81, 95% CrI 0.31 to 2.17.
There was no evidence of diBerences between the treatments in
the remaining direct comparisons or in the network meta-analysis
(i.e. the remaining direct comparisons or network meta-analyses
were not statistically significant; very low-certainty evidence; Table
4; Summary of findings 2).
There were no subgroup diBerences. There was no change in
the results by using the best-worst and worst-best scenarios for
imputing missing data.
Health-related quality of life (maximal follow-up)
None of the trials reported quality of life (maximal follow-up).
Serious adverse events
Four trials (1425 participants) reported serious adverse events
(proportion) (Neuhaus 2002; Boillot 2005; Calmus 2010; Klintmalm
2014). A total of three treatments were compared in these trials. All
the trials were connected to the network. There were no triangular
or quadrangular loops created using evidence from the four trials;
therefore, inconsistency was not checked. We used the fixed-eBect
model because it had equivalent results and model fit as the
random-eBects model. There was no evidence of diBerences in any
of the direct comparisons or network meta-analysis (i.e. there was
no statistically significant diBerence in any of the comparisons; very
low-certainty evidence; Table 4; Summary of findings 2). There was
no change in the results by using the best-worst and worst-best
scenarios for imputing missing data.
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Two trials (185 participants) reported serious adverse events
(number of events) (Yoshida 2005; Benitez 2010). A total of
three treatments were compared in these trials. All the trials
were connected to the network. There were no triangular or
quadrangular loops created using evidence from the two trials;
therefore, inconsistency was not checked. Only one trial was
included in each of the comparisons; therefore, only the fixed-eBect
model is applicable. There was no evidence of diBerences in any of
the direct comparisons or network meta-analysis (i.e. there was no
statistically significant diBerence in any of the comparisons; very
low-certainty evidence; Table 4; Summary of findings 2).
Renal failure
One trial (698 participants) reported renal failure and compared
daclizumab plus glucocorticosteroids versus glucocorticosteroids
alone (Boillot 2005). Only one trial was included in the comparison;
therefore, only the estimate from the single trial is applicable.
There was no evidence of diBerences between daclizumab plus
glucocorticosteroids versus glucocorticosteroids alone (HR 1.11,
95% CrI 0.44 to 2.78; 1 trial, 698 participants; very low-certainty
evidence; Summary of findings 2). There was no change in the
results by using the best-best and worst-worst scenarios for
imputing missing data.
Any adverse events
Four trials (1413 participants) reported any adverse events
(proportion) (Neuhaus 2002; Boillot 2005; Calmus 2010; Neumann
2012). A total of four treatments were compared in these trials. All
the trials were connected to the network. There were no triangular
or quadrangular loops created using evidence from the four trials;
therefore, inconsistency was not checked. We used the fixed-eBect
model because it had equivalent results and model fit as the
random-eBects model. There was no evidence of diBerences in any
of the direct comparisons or network meta-analysis (i.e. there was
no statistically significant diBerence in any of the comparisons; very
low-certainty evidence; Table 4; Summary of findings 2). There was
no change in the results by using the best-worst and worst-best
scenarios for imputing missing data.
Two trials (140 participants) reported any adverse events (number
of events) (Lupo 2008; Boillot 2009). A total of three treatments
were compared in these trials. All the trials were connected to the
network. There were no triangular or quadrangular loops created
using evidence from the two trials; therefore, inconsistency was not
checked. Only one trial was included in each of the comparisons;
therefore, only the fixed-eBect model is applicable. There was no
evidence of diBerences in any of the direct comparisons or network
meta-analysis (i.e. there was no statistically significant diBerence
in any of the comparisons; very low-certainty evidence; Table 4;
Summary of findings 2).
Liver retransplantation at maximal follow-up
Eight trials (1301 participants) reported liver retransplantation at
maximal follow-up (Tisone 1999; Bogetti 2005; Boillot 2005; Yoshida
2005; Lupo 2008; Boillot 2009; Calmus 2010; Garcia-Saenz-De-
Sicilia 2014). A total of six treatments were compared in these trials.
Two trials were not connected to the network because they had
zero events in both arms (Tisone 1999; Bogetti 2005); two trials
were not connected to the network because they were the only
trials for the comparison and had zero events in one of the arms
(Boillot 2009), or the treatments were not connected to the network
(Garcia-Saenz-De-Sicilia 2014); therefore, we excluded these four
trials from the network.
The network had three connected treatments (4 trials, 1092
participants). There were no triangular or quadrangular loops
created using evidence from the four trials connected to the
network; therefore, inconsistency was not checked. We used the
fixed-eBect model because it had equivalent results and model fit
as the random-eBects model. There was no evidence of diBerences
in any of the direct comparisons or network meta-analysis (i.e. there
was no statistically significant diBerence in any of the comparisons;
very low-certainty evidence; Table 4; Summary of findings 2). There
was no change in the results by using the best-worst and worst-best
scenarios for imputing missing data.
The results from the trials excluded from the network are as follows.
• Anti-thymocyte globulin plus glucocorticosteroids (0/56;
0%) versus glucocorticosteroids (1/59; 1.7%) (2 trials, 115
participants; very low-certainty evidence).
• No induction immunosuppression (0/23; 0%) versus
glucocorticosteroids (0/22; 0%) (1 trial, 45 participants; very low-
certainty evidence).
• Anti-thymocyte globulin versus anti-thymocyte globulin plus
glucocorticosteroids: HR 2.81, 95% CrI 0.22 to 90.29; 1
trial, 49 participants; very low-certainty evidence, i.e. anti-
thymocyte globulin plus glucocorticosteroids versus anti-
thymocyte globulin: HR 0.36, 95% CrI 0.01 to 4.62.
Gra4 rejection (any)
Twenty-two trials (2977 participants) reported graH rejection (any)
(Tisone 1999; Belli 2001; Washburn 2001; Neuhaus 2002; Eason
2003; Bogetti 2005; Boillot 2005; Yoshida 2005; Llado 2006; Lu 2006;
Kato 2007; Schmeding 2007; Lupo 2008; Washburn 2008; Boillot
2009; Benitez 2010; Calmus 2010; Klintmalm 2011; Neumann 2012;
Garcia-Saenz-De-Sicilia 2014; Klintmalm 2014; Kathirvel 2018). A
total of eight treatments were compared in these trials. All the
trials were connected to the network. There was no evidence of
inconsistency according to model fit, inconsistency factor, and the
between-design variance 0.38 (95% CrI 0.00 to 15.28). We used the
fixed-eBect model because it had equivalent results and model fit
as the random-eBects model.
There was no evidence of diBerences in any of the direct
comparisons or network meta-analysis (i.e. there was no
statistically significant diBerence in any of the comparisons; very
low-certainty evidence; Table 4; Summary of findings 2). There were
no subgroup diBerences. There was no change in the results by
using the best-worst and worst-best scenarios for imputing missing
data.
Gra4 rejections requiring treatment
Six trials (1176 participants) reported graH rejections requiring
treatment (Washburn 2001; Eason 2003; Boillot 2005; Lupo 2008;
Neumann 2012; Klintmalm 2014). A total of six treatments
were compared in these trials. All the trials were connected to
the network. There were no triangular or quadrangular loops;
therefore, inconsistency was not checked. We used the fixed-eBect
model because it had equivalent results and model fit as the
random-eBects model.
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There was no evidence of diBerences in any of the direct
comparisons or network meta-analysis (i.e. there was no
statistically significant diBerence in any of the comparisons; very
low-certainty evidence; Table 4; Summary of findings 2). There were
no subgroup diBerences. There was no change in the results by
using the best-worst and worst-best scenarios for imputing missing
data.
Costs
None of the trials reported costs of treatment.
Subgroup and sensitivity analysis
We have presented the subgroup and sensitivity analyses under
each outcome, when applicable
Assessment of reporting biases
Since there was no meaningful way in which to rank these studies
(i.e. there was no specific change in the risk of bias in the studies,
sample size, or the control group used over time), we did not
perform the comparison-adjusted funnel plot. However, lack of
reporting of outcomes for mortality, graH failure, and adverse
events expected to be assessed in trials of this nature, may indicate
reporting biases.
D I S C U S S I O N
Summary of main results
We performed a systematic review and network meta-analysis of
the major induction immunosuppression regimens used in people
who have undergone liver transplantation. We included a total of
25 trials, including a total of 3271 participants in this review. We
compared a total of eight interventions in these trials. We included
a total of 23 trials, including 3017 participants for one or more
outcomes of this review (Tisone 1999; Belli 2001; Washburn 2001;
Neuhaus 2002; Eason 2003; Bogetti 2005; Boillot 2005; Yoshida
2005; Llado 2006; Lu 2006; Kato 2007; Schmeding 2007; Lupo
2008; Washburn 2008; Boillot 2009; Benitez 2010; Calmus 2010;
Klintmalm 2011; Neumann 2012; Ramirez 2013; Garcia-Saenz-De-
Sicilia 2014; Klintmalm 2014; Kathirvel 2018).
Overall, 7.4% of the trial participants in the glucocorticosteroids
group died over a follow-up period ranging between three and
76 months (median: 12 months). This is similar to the one-
year patient survival for elective first liver transplants in the UK
(NHSBT 2018). Although the direct evidence did not demonstrate
any significant diBerences in all-cause mortality, the network
meta-analysis suggested that all-cause mortality was lower with
basiliximab alone compared with glucocorticosteroids alone, anti-
thymocyte globulin plus glucocorticosteroid, and daclizumab plus
glucocorticosteroids. However, it should be noted that these
findings are based on small trials with high risk of bias (see Quality
of the evidence). Only two trials (131 participants) reported the
direct comparisons between basiliximab and glucocorticosteroids
induction (Lupo 2008; Kathirvel 2018), and the analysis of these
two trials did not demonstrate clinical significance (odds ratio
(OR) 0.50, 95% credible interval (CrI) 0.02 to 12.55). The remaining
information was from indirect comparisons. Although there was
no evidence of inconsistency (i.e. 'incoherence' according to
GRADE terminology), one cannot rule out inconsistency completely
using the diBerent methods that were possible (we could not
obtain convergence for design-by-treatment model despite various
measures): the power to detect inconsistency may have been low.
This introduces some uncertainty in the results. In terms of graH
failure, 12.2% of the trial participants in the glucocorticosteroids
group had graH failure (i.e. required retransplantation or died) over
a follow-up period of three to 60 months. The direct comparison
showed that basiliximab had lower graH failure compared with
glucocorticosteroids alone. However, this is based on a single trial
including 47 participants (Lupo 2008). Therefore, there is large
uncertainty in this outcome as well.
There was no evidence of diBerences (i.e. no statistically significant
diBerences) in any of the remaining direct comparisons or
network meta-analysis. However, the CrIs were wide, and clinically
important diBerences in the outcomes cannot be ruled out.
In the median control group (glucocorticosteroids alone induction)
graH failure was 12.2%. The sample size required to detect a relative
risk reduction of 30% in the experimental group (basiliximab
alone induction) (upper CrI observed in the only trial of 47
participants reporting on graH failure), type I error of 5%, and type
II error of 20% is 2176 participants. This will probably require a
multicentric international trial, but it is possible to conduct. Given
that most centres (at least in the UK), use some form of induction
immunosuppression, it is not clear whether patients will accept
being randomised to 'no active intervention' ('no intervention'
or 'placebo') and clinicians will randomise participants in a trial
with 'no active intervention' as one of the arms. Therefore, further
involvement of patients and clinicians in qualitative research is
necessary in the design of such a trial.
Overall completeness and applicability of evidence
The trials included mostly people undergoing elective primary liver
transplantation (i.e. for liver cirrhosis or hepatocellular carcinoma),
but also included people of diBerent aetiologies for liver cirrhosis.
Therefore, the findings of this review are applicable only for
people undergoing elective liver transplantation. However, there
is no specific physiological reason as to why people undergoing
retransplantation or those undergoing liver transplantation
for acute liver failure will react diBerently to the induction
immunosuppression. Many studies also excluded people with
HIV and those with renal impairment prior to undergoing liver
transplantation. Induction immunosuppression and the safety
profile of drugs may be diBerent in those with these conditions.
Therefore, the findings of this review are applicable only to
those without HIV or renal impairment prior to undergoing liver
transplantation.
Certainty of the evidence
The overall certainty of evidence was low or very low for all the
outcomes. One of the main reasons for the very low-certainty of
evidence was the unclear or high risk of bias in most of the trials. It is
possible to perform trials of low risk of bias in the field. To perform
a low risk of bias trial, randomisation can be performed using
standard methods, for example, web-based central randomisation;
blinding of parties involved can be achieved by using a double-
placebo design even if two interventions at diBerent frequencies
are given (i.e. a placebo for intervention and a placebo for control);
an intention-to-treat analysis can be performed; and a protocol can
be published prior to recruitment. None of these have any major
ethical considerations; therefore, a low risk of bias trial is very much
feasible.
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Another major reason for very low-certainty of evidence is
imprecision: the trials had small sample sizes and the CrIs
overlapped clinically significant benefits and clinically significant
harms for most comparisons. Therefore, future trials should
be adequately powered with sample sizes, as described in the
previous section.
We used clinical outcomes; therefore, there is no issue of
indirectness due to outcomes. There was no suggestion that
the potential eBect modifiers were systematically diBerent across
comparisons (i.e. there was no concern regarding the transitivity
assumption). There was no evidence of inconsistency in most of
the outcomes (except graH failure). However, one cannot rule out
inconsistency ('incoherence' according to GRADE terminology).
There was no meaningful way to rank these studies (i.e. there
was no specific change in the risk of bias in the studies, sample
size, or the control group used over time); we have completed a
thorough search for studies on eBectiveness. However, some trials
did not report mortality or graH failure (only 18/25 trials reported
mortality and only 10/25 trials reported graH failure). It is extremely
likely that trials in this group of patients measured these outcomes;
nevertheless, many trials did not report these outcomes suggesting
reporting bias for these outcomes.
Potential biases in the review process
We selected a range of databases to search without using any
language restrictions and conducted the network meta-analysis
according to National Institute for Health and Care Excellence
(NICE) Decision Support Unit (DSU) guidance. In addition, we
have analysed the data using the fixed-eBect and random-
eBects models, and assessed and reported inconsistency whenever
possible. These are the strengths of the review process.
We have excluded studies that compared variations in duration
or dose in the diBerent interventions. In particular, we
have excluded studies where glucocorticosteroids were given
even for a short period, even when trials were comparing
glucocorticosteroid-sparing regimens (but which included some
doses of glucocorticosteroids) with regimes that included
glucocorticosteroids for a longer period of time. Hence this review
does not provide information on whether one variation is better
than another. Another major limitation of this review was the
paucity of data: most trials were small trials. This paucity of data
decreases the confidence in the results.
All of the network meta-analyses included only sparse data from
trials, most of which were at high risk of bias. However, the potential
eBect modifiers in the trials that reported them were broadly
similar across comparisons. Therefore, the concern regarding the
transitivity assumption is low. However, lack of transitivity cannot
be ruled out.
We included only randomised clinical trials, which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. Therefore, it is possible that we have missed a
large number of non-randomised studies addressing reporting of
harms. A significant eBort is required to identify non-randomised
studies and assess the risk of bias in those studies. Approximately,
37.6% of participants who received glucocorticosteroids developed
one or more serious adverse events, and there were 93.4 serious
adverse events per 100 participants; 97.1% of participants who
received glucocorticosteroids developed one or more of 'any'
adverse event(s), and there were 161.2 'any' adverse events per 100
participants. This seems to indicate that the harms were reported
adequately in the trials that reported about harms. Furthermore,
trials can be powered on graH failure, which will determine whether
an intervention should be used, even if there is an increase in
adverse events; therefore, performing a systematic review of harms
seems unnecessary.
Agreements and disagreements with other studies or
reviews
This is the first network meta-analysis on the topic. There have
been two reviews on induction immunosuppression involving the
interventions that were compared in this review (Penninga 2014a;
Penninga 2014b). Both reviews highlighted the uncertainty in the
role of diBerent antibody induction regimens in people undergoing
liver transplantation. Despite the diBerent methodologies used (in
terms of interventions included and methods used for analysis), we
broadly agree that there is considerable uncertainty in the role of
the diBerent antibody induction immunosuppression regimens for
people undergoing liver transplantation.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Based on low-certainty evidence, basiliximab induction
may decrease mortality and graH failure compared to
glucocorticosteroids induction in people undergoing liver
transplantation. However, there is considerable uncertainty about
this finding because this information is based on small trials
at high risk of bias. The evidence is uncertain regarding the
eBects of diBerent induction immunosuppressants on other clinical
outcomes, including graH rejections.
Implications for research
Further well-designed randomised clinical trials are necessary.
Some aspects of the design of the randomised clinical trials should
be as follows.
• Study design: double-blind, placebo-controlled, parallel,
randomised clinical trial.
• Participants: people undergoing liver transplantation.
• Intervention: basiliximab induction.
• Control: glucocorticosteroid induction or no active intervention
(if it is feasible to include this as one of the control groups).
• Outcomes
* Primary outcome: graH failure (1 year)
* Secondary outcomes: all-cause mortality (1 year), health-
related quality of life, adverse events, graH rejections
requiring treatment
* Minimum length of follow-up: one year
• Sample size: for a simple two-arm, parallel, randomised
clinical trial, the sample size required to detect a relative risk
reduction of 30% in the experimental group from the control
group proportion of 12.2% graH failure (median proportion in
glucocorticosteroid induction), type I error of 5%, and type II
error of 20%, 2176 participants are required.
• Other aspects: trials need to be conducted and
reported according to the SPIRIT (Standard Protocol Items:
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Recommendations for Interventional Trials) statement (Chan
2013) and CONSORT statement (Schulz 2010).
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Methods Randomised clinical trial
Participants Country: Italy
Period of recruitment: 1997-1999
Number randomised: 19
Post-randomisation dropouts: not stated
Revised sample size: 19
Average age (years): not stated
Females: not stated
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not stated
Maintenance immunosuppression used during induction immunosuppression: cyclosporin A plus aza-
thioprine
Altered immunosuppression after withdrawal: yes (azathioprine was dropped)
Interventions Group 1: anti-thymocyte globulin (n = 8)
Further details: Rabbit anti-thymocyte globulin for 5 days (no further details on the dose, frequency)
Group 2: anti-thymocyte globulin + glucocorticosteroids (n = 11)
Further details: rabbit anti-thymocyte globulin for 5 days + glucocorticosteroids for 3 months (no fur-
ther details on the dose, frequency)
Belli 2001 
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Outcomes Outcomes reported: graH rejection (any)
Follow-up (months): 22
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: this is a three-armed trial, but only two arms are eligible for inclu-
sion in the review. There were post-randomisation dropouts. The number of
dropouts in each group and the reasons for dropouts were not reported
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on mortality, graH loss, or adverse events




Methods Randomised clinical trial
Participants Country: Spain
Period of recruitment: 2006-2008
Number randomised: 37
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 37
Average age (years): 52
Females: 7 (18.9%)
Primary transplantation: 37 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 25 (67.6%)
Viral-related cirrhosis: 2 (5.4%)
Autoimmune disease-related cirrhosis: 0 (0%)
HCC: 9 (24.3%)
Others: 11 (29.7%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus
Benitez 2010 
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Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• autoimmune liver disease
• HCV and/or HIV infection
• liver transplantation with partial graH
• previous use of rabbit immunoglobulins
• acute liver failure
Interventions Group 1: anti-thymocyte globulin + glucocorticosteroids (n = 21)
Further details: anti-thymoglobulin 9 mg/kg was started 2–3 h before transplantation and infused i.v.
over a 6-h period preceded by 500 mg methylprednisolone i.v.
Group 2: glucocorticosteroids (n = 16)
Further details: corticosteroids were administered as follows: 1 g methylprednisolone i.v. during the
surgical procedure, 20 mg prednisone daily during the first post-transplant month, and thereafter dos-
es were tapered down until complete discontinuation during post-transplant months 3– 6
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, serious adverse
events (number of events), graH rejection (any)
Follow-up (months): 12
Notes Source of funding (quote): "This work was supported by grants from Fresenius Biotech GmbH, Astellas
and by the Ministerio de Educaci on y Ciencia, Spain"
Trial name/trial registry number: NCT00436722
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










High risk Quote: "prospective, randomized, open label, controlled trial"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events
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Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: not stated
Number randomised: 22
Post-randomisation dropouts: not stated
Revised sample size: 22
Average age (years): 53
Females: 9 (40.9%)
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: 3 (13.6%)
Viral-related cirrhosis: 15 (68.2%)
Autoimmune disease-related cirrhosis: 4 (18.2%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus
Altered immunosuppression after withdrawal: no
Interventions Group 1: anti-thymocyte globulin + glucocorticosteroids (n = 12)
Further details: anti-thymoglobulin (1.5 mg/kg per dose) during the anhepatic phase and two doses
every other day postoperatively + methylprednisolone 500 mg i.v. preoperatively and a postoperative
prednisone taper; the steroids were discontinued by postoperative day 90
Group 2: glucocorticosteroids (n = 10)
Further details: methylprednisolone 500 mg i.v. preoperatively and a postoperative prednisone taper;
the steroids were discontinued by postoperative day 90
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, liver transplan-
tation at maximal follow-up, graH rejection (any)
Follow-up (months): 3
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: this information was not available
Bogetti 2005 
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Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: multicentric (Europe)
Period of recruitment: 2000-2002
Number randomised: 708
Post-randomisation dropouts: 10 (1.4%)
Revised sample size: 698
Reasons for post-randomisation dropouts: did not receive study medication (8), not transplanted (1),
did not provide informed consent (1)
Average age (years): 51
Females: 221 (31.7%)
Primary transplantation: 698 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: 47 (6.7%)
HCC: 103 (14.8%)
Others: 52 (7.4%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• multiorgan transplants
• previous organ transplants
• living-related liver transplants
• patients or donors known to be HIV–positive
Interventions Group 1: daclizumab + glucocorticosteroids (n = 351)
Further details: daclizumab 2 intravenous doses of 2 mg/kg before reperfusion and 1 mg/kg between
postoperative days 7 and 10 + methylprednisolone (500 mg) as a single intravenous bolus before reper-
fusion
Group 2: glucocorticosteroids (n = 347)
Further details: methylprednisolone (500 mg) as a single intravenous bolus before reperfusion + re-
ceived oral prednisone 15–20 mg/day during month 1, 10–15 mg/day during month 2, and 5–10 mg/day
during month 3
Boillot 2005 
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Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, serious adverse
events (number of people), any adverse events (number of people), renal failure, liver transplantation
at maximal follow-up, graH rejection (any), graH rejection (requiring treatment)
Follow-up (months): 3
Notes Source of funding (quote): "Supported by Fujisawa GmbH, Munich, Germany"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





High risk Quote: "open-label, randomized, multicenter, parallel-group"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: France
Period of recruitment: 1997-1999
Number randomised: 93
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 93
Average age (years): 50
Females: 39 (41.9%)
Primary transplantation: 93 (100.0%)
Reason for transplantation
Boillot 2009 
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Alcohol-related cirrhosis: 41 (44.1%)
Viral-related cirrhosis: 24 (25.8%)
Autoimmune disease-related cirrhosis: 10 (10.8%)
HCC (associated): 12 (12.9%)
Others: 18 (19.4%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• multiorgan transplantation, or living donor transplantation
• ABO blood group–incompatible graHs
• serum creatinine above 180 micromol/L
• HIV seropositivity
Interventions Group 1: anti-thymocyte globulin + glucocorticosteroids (n = 44)
Further details: anti-thymocyte globulin 100 mg OD for 6 days (started intraoperatively) + methyl pred-
nisolone 500 mg intraoperatively, and thereafter, patients received 20 mg per day, which was progres-
sively tapered to 5 mg. Whenever possible, patients were withdrawn from steroids after 3 months post-
transplantation
Group 2: glucocorticosteroids (n = 49)
Further details: methyl prednisolone 500 mg intraoperatively, and thereafter, patients received 20 mg
per day, which was progressively tapered to 5 mg. Whenever possible, patients were withdrawn from
steroids after 3 months post-transplantation
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, any adverse
events (number of events), liver transplantation at maximal follow-up, graH rejection (any)
Follow-up (months): 60
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After randomization according to a randomization table"
Allocation concealment
(selection bias)





High risk Quote: "randomized, open-label study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "randomized, open-label study"
Incomplete outcome data
(attrition bias) 
Low risk Comment: there were no post-randomisation dropouts
Boillot 2009  (Continued)
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Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: France
Period of recruitment: 2002-2004
Number randomised: 207
Post-randomisation dropouts: 8 (3.9%)
Revised sample size: 199
Reasons for post-randomisation dropouts: elevated serum creatinine, death, hepatic arterial thrombo-
sis, retransplantation for non-primary graH function, acute renal failure
Average age (years): 53
Females: 48 (24.1%)
Primary transplantation: 199 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 62 (31.2%)
Viral-related cirrhosis: 22 (11.1%)
Autoimmune disease-related cirrhosis: not stated
HCC: 81 (40.7%)
Others: 15 (7.5%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: yes (mycophenolate was dropped). Glucocorticosteroids
were also continued as part of maintenance immunosuppression
Other exclusion criteria:
• multiorgan transplantation
• serum creatinine level more than 180 micromol/L at 12 hr post-transplant
• ABO blood group incompatibility
• Positive for HIV
Interventions Group 1: daclizumab + glucocorticosteroids (n = 98)
Further details: daclizumab: first dose was 2.0 mg/kg administered at 12-hr post-transplant, the second
dose was 1.0 mg/kg administered between days 7 and 10 + glucocorticosteroids were initiated at 15 to
20 mg/day until the end of month 1, decreased to 10 to 15 mg/day until the end of month 2, and then
decreased to 5 to 10 mg/day for the remainder of the study
Group 2: glucocorticosteroids (n = 101)
Further details: glucocorticosteroids were initiated at 15 to 20 mg/day until the end of month 1, de-
creased to 10 to 15 mg/day until the end of month 2, and then decreased to 5 to 10 mg/day for the re-
mainder of the study
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, serious adverse
events (number of people), any adverse events (number of people), liver transplantation at maximal
follow-up, graH rejection (any)
Follow-up (months): 24
Calmus 2010 
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Notes Source of funding (quote): "The work was supported by Astellas Pharma, France"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Computer-generated randomization was 1:1 and stratified according
to the local center"
Allocation concealment
(selection bias)





High risk Quote: "randomized, open-label, comparative study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: there were post-randomisation dropouts. These were probably re-
lated to the intervention and were likely to affect the outcomes
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 1999-2002
Number randomised: 119
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 119
Average age (years): not stated
Females: not stated
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: 12 (10.1%)
Viral-related cirrhosis: 69 (58.0%)
Autoimmune disease-related cirrhosis: 15 (12.6%)
HCC: not stated
Others: 20 (16.8%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: yes (mycophenolate was dropped)
Interventions Group 1: anti-thymocyte globulin (n = 60)
Eason 2003 
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Further details: anti-thymocyte globulin: 1.5 mg/kg intravenously (i.v.) beginning during the anhepatic
phase and continued for 6 hours post-OLT. A second dose of 1.5 mg/kg was administered post-OLT day
1, making the total dose 3 mg/kg for each patient
Group 2: glucocorticosteroids (n = 59)
Further details: methylprednisolone 1000 mg i.v. during the anhepatic phase. A steroid taper was insti-
tuted beginning at 100 mg twice daily post-transplant day 1 down to 20 mg/d of prednisone by post-
transplant day 6. Patients were weaned oB prednisone by 3 months post-transplant
Outcomes Outcomes reported: graH rejection (any), graH rejection (requiring treatment)
Follow-up (months): 19
Notes Source of funding (quote): "Supported in part by an unrestricted educational grant from Sangstat"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: Italy
Period of recruitment: 1998-2001
Number randomised: 140
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 140
Average age (years): 53
Females: 35 (25.0%)
Primary transplantation: 140 (100.0%)
Reason for transplantation
Filipponi 2004 
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Alcohol-related cirrhosis: 0 (0.0%)
Viral-related cirrhosis: 140 (100.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: cyclosporin plus aza-
thioprine
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• acute liver failure
• ABO incompatibility
• HIV-positive
• serum creatinine 265 micromol/L or above, or dialysis
Interventions Group 1: basiliximab (n = 69)
Further details: basiliximab 20 mg intravenously (i.v.) on day 0 (within 6 hr after reperfusion of the graH)
and on day 4 + placebo
Group 2: basiliximab+glucocorticosteroids (n = 71)
Further details: basiliximab 20 mg intravenously (i.v.) on day 0 (within 6 hr after reperfusion of the graH)
and on day 4 + methylprednisolone 500 mg i.v. intraoperatively, 125 mg on day 1, 40 mg on day 2, and
subsequently oral prednisone 25 mg/day up to day 30, 15 mg/day in month 2, and 5 mg/day in month 3
Outcomes None of the outcomes of interest were reported
Notes Source of funding (quote): "This work was supported by Novartis Pharma AG and Novartis Farma SpA"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer-generated randomization list"
Allocation concealment
(selection bias)






Low risk Quote: "Blinding was achieved by using matching placebo vials and by insert-
ing the tablets into capsules designed for double-blind clinical trials"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Blinding was achieved by using matching placebo vials and by insert-




Low risk Comment: there were no post-randomisation dropouts
Filipponi 2004  (Continued)
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Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected





Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 2008-2010
Number randomised: 100
Post-randomisation dropouts: 51 (51.0%)
Revised sample size: 49
Reasons for post-randomisation dropouts: did not have HCV
Average age (years): 55
Females: 15 (30.6%)
Primary transplantation: 49 (100%)
Reason for transplantation
Alcohol-related cirrhosis: 0 (0.0%)
Viral-related cirrhosis: 49 (100.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: yes (mycophenolate was dropped). Glucocorticosteroids
were also continued as part of maintenance immunosuppression
Other exclusion criteria:
• multiorgan transplantation
Interventions Group 1: anti-thymocyte globulin (n = 23)
Further details: methylprednisolone: 500 to 1000 mg of was administered intraoperatively. The dosage
was tapered to 5 mg/day by day 90 after liver transplantation
Group 2: anti-thymocyte globulin + glucocorticosteroids (n = 26)
Further details: anti-thymocyte globulin: 1.5 mg/kg on day 0 (during the anhepatic phase), days 2, 4,
and 6 + methylprednisolone: 500 to 1000 mg was administered intraoperatively. The dosage was ta-
pered to 5 mg/day by day 90 after liver transplantation
Outcomes Outcomes reported: mortality at maximal follow-up, liver transplantation at maximal follow-up, graH
rejection (any)
Follow-up (months): 21
Notes Source of funding (quote): "The authors have no financial disclosures or conflict of interests"
Trial name/trial registry number: NCT00564538
Attempts were made to contact the authors in August 2019.
Risk of bias
Garcia-Saenz-De-Sicilia 2014 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





High risk Quote: "open label, single-center, randomized"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: only patients with hepatitis C infection were included. It is not clear
whether this is related to the intervention and outcome
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available, but the authors report on-
ly on a subgroup of patients




Methods Randomised clinical trial
Participants Country: India
Period of recruitment: not stated
Number randomised: 84
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 84
Average age (years): 48
Females: not stated
Primary transplantation: 84 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not state
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus azathio-
prine
Kathirvel 2018 
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Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• cadaveric liver transplantation
• multiorgan transplantation
• ABO incompatibility
Interventions Group 1: basiliximab (n = 42)
Further details: basiliximab (no further details)
Group 2: glucocorticosteroids (n = 42)
Further details: glucocorticosteroids (no further details)
Outcomes Outcomes reported: graH rejection (any)
Follow-up (months): 10
Notes Source of funding: not stated
Trial name/trial registry number: CTRI/2017/08/009508
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 1999-not stated
Number randomised: 100
Post-randomisation dropouts: 30 (30.0%)
Kato 2007 
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Revised sample size: 70
Reasons for post-randomisation dropouts: early graH failure or death or did not have biopsy
Average age (years): 51
Females: 19 (27.1%)
Primary transplantation: 70 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 0 (0.0%)
Viral-related cirrhosis: 70 (100.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus or
tacrolimus plus mycophenolate mofetil (mycophenolate was added as immunosuppressive therapy af-
ter 2002)
Altered immunosuppression after withdrawal: no
Interventions Group 1: daclizumab (n = 31)
Further details: daclizumab was given intraoperatively in a 2 mg/kg intravenous injection, with five ad-
ditional doses of 1 mg/kg given intravenously every 2 weeks starting on the seventh postoperative day
Group 2: glucocorticosteroids (n = 39)
Further details: methylprednisolone 1 g was given intraoperatively. Methylprednisolone was continued
with the tapering dose of: 200 mg (day 1), 160 mg (day 2), 120 mg (day 3), 80 mg (day 4), 40 mg (day 5),
and 20 mg (day 6). Methylprednisolone was given orally at the dose of 20 mg per day after completion
of the above mentioned tapering plan and was scheduled to be tapered oB completely in the control
arm by 3 months post-transplant
Outcomes Outcomes reported: graH rejection (any)
Follow-up (months): 12
Notes Source of funding (quote): "This study was supported by an investigator initiated research grant from
Roche Laboratories (ZEN097)"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All protocol biopsy specimens were reviewed by a single pathologist
(P.R.) in a blinded fashion at the time of biopsy"
Comment: the only outcome of interest for this review in this trial was graH re-




High risk Comment: there were post-randomisation dropouts, many of which are proba-
bly related to the intervention and outcome
Kato 2007  (Continued)
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Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on mortality, graH failure, or adverse events adequately, even though it is
clear that this information was collected




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: not stated
Number randomised: 218
Post-randomisation dropouts: 3 (1.4%)
Revised sample size: 215
Reasons for post-randomisation dropouts: HCV RNA negative at the time of transplantation and subse-
quent testing
Average age (years): 51
Females: 56 (26.0%)
Primary transplantation: 215 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 0 (0.0%)
Viral-related cirrhosis: 215 (100.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no (glucocorticosteroids were continued as mainte-
nance immunosuppression in the group that received glucocorticosteroids)
Interventions Group 1: daclizumab (n = 143)
Further details: daclizumab: 2 mg/kg on days 0 (within 12 hours) and 3 and 1 mg/kg on day 8
Group 2: glucocorticosteroids (n = 72)
Further details: methylprednisolone 500 to 1000 mg (or the equivalent of intravenous hydrocortisone
or dexamethasone) was administered intraoperatively; the dosage was orally tapered to 10 mg/day by
day 30 and to 5 mg/day by day 90
Outcomes Outcomes reported: mortality at maximal follow-up, graH rejection (any)
Follow-up (months): 21
Notes Source of funding (quote): "This study was supported by a grant from Roche"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available
Klintmalm 2011 
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High risk Quote: "open-label, randomized, prospective, multicentre"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 2008-2011
Number randomised: 153
Post-randomisation dropouts: 6 (3.9%)
Revised sample size: 147
Reasons for post-randomisation dropouts: did not receive transplantation or study medication
Average age (years): 54
Females: 43 (29.3%)
Primary transplantation: 147 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not stated
Maintenance immunosuppression used during induction immunosuppression: belatacept plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• ABO blood group incompatibility.
• donation after cardiac death
• living-donor recipients
Interventions Group 1: basiliximab+glucocorticosteroids (n = 50)
Further details: basiliximab: 20 mg i.v. was given on days 1 and 5
Group 2: glucocorticosteroids (n = 97)
Further details: corticosteroids (no drug name) on days 1–5, which was tapered to ≤ 10 mg/day by day
30 and ≤ 5 mg/day by day 90
Klintmalm 2014 
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Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, serious adverse
events (number of people), graH rejection (any), graH rejection (requiring treatment)
Follow-up (months): 12
Notes Source of funding (quote): "This study was supported by Bristol-Myers Squibb"
Trial name/trial registry number: NCT00555321
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "an interactive voice response system with centralized randomization"
Allocation concealment
(selection bias)





Low risk Quote: "The trial was fully blinded to patients and study personnel with re-
spect to belatacept dosing regimen (HD or LD) and basiliximab assignment
(through the use of placebo infusions)"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The trial was fully blinded to patients and study personnel with re-
spect to belatacept dosing regimen (HD or LD) and basiliximab assignment




Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events
Other bias High risk Comment: the dose of other immunosuppressive drugs were high in half the




Methods Randomised clinical trial
Participants Country: Spain
Period of recruitment: 2001-2004
Number randomised: 200
Post-randomisation dropouts: 2 (1.0%)
Revised sample size: 198
Reasons for post-randomisation dropouts: protocol violations
Average age (years): 54
Females: 43 (21.7%)
Primary transplantation: 198 (100.0%)
Llado 2006 
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Reason for transplantation
Alcohol-related cirrhosis: 55 (27.8%)
Viral-related cirrhosis: 60 (30.3%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 63 (31.8%)
Others: 20 (10.1%)
Maintenance immunosuppression used during induction immunosuppression: cyclosporin A plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• transplant for fulminant liver disease
• multiorgan transplant
• HIV infection
Interventions Group 1: basiliximab (n = 96)
Further details: basiliximab as two 20 mg doses: the first dose was administered within 6 hours of
reperfusion (day 0), and the second dose on day 4 after transplantation
Group 2: basiliximab + glucocorticosteroids (n = 102)
Further details: basiliximab as two 20 mg doses: the first dose was administered within 6 hours of
reperfusion (day 0), and the second dose on day 4 after transplantation + methylprednisolone (500 mg)
as a single intravenous bolus before reperfusion; and afterwards, 0.5 mg/kg/day methylprednisolone
until day 5, 0.25 mg/kg/day from day 5 to day 30, and 0.15 mg/kg/day from day 30 to day 90. After-
wards, steroids were withdrawn
Outcomes Outcomes reported: mortality at maximal follow-up, graH rejection (any)
Follow-up (months): 6
Notes Source of funding (quote): "they received funding from the drug companies involved to carry out their
research"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)






High risk Quote: "an open-label, not-blinded"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "an open-label, not-blinded"
Llado 2006  (Continued)
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Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: China
Period of recruitment: 2001-2004
Number randomised: 67
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 67
Average age (years): not stated
Females: not stated
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not stated
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil





Interventions Group 1: daclizumab + glucocorticosteroids (n = 40)
Further details: daclizumab 1 mg/kg on the day of surgery and 4th postoperative day + glucocorticos-
teroids for 3 months (no further details)
Group 2: glucocorticosteroids (n = 27)
Further details: glucocorticosteroids for 3 months (no further details)
Outcomes Outcomes reported: mortality at maximal follow-up, graH rejection (any)
Follow-up (months): 6
Lu 2006 
Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Notes Source of funding: government agency
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on graH loss and adverse events adequately, even though it is clear that
this information was collected




Methods Randomised clinical trial
Participants Country: Italy
Period of recruitment: 2002-2005
Number randomised: 47
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 47
Average age (years): 52
Females: 6 (12.8%)
Primary transplantation: 47 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: 40 (85.1%)
Lupo 2008 
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Autoimmune disease-related cirrhosis: not stated
HCC: 19 (40.4%)
Others: 7 (14.9%)
Maintenance immunosuppression used during induction immunosuppression: cyclosporin A
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• ABO blood group incompatibility
• living-donor recipients
Interventions Group 1: basiliximab (n = 26)
Further details: basiliximab 20 mg intravenous infusion within 8 hr after reperfusion of the graH on day
0 and the second dose (20 mg) on day 4 after transplantation
Group 2: glucocorticosteroids (n = 21)
Further details: hydrocortisone 200 mg intravenous per day until the resumption of oral feeding, when
the dose was tapered to 20 mg per day of oral prednisolone. This dose was reduced by 5 mg every 21
days and the drug was suspended within 90 days after transplantation
Outcomes Outcomes reported: any adverse events (number of events), liver transplantation at maximal fol-
low-up, graH rejection (any), graH rejection (requiring treatment)
Follow-up (months): 22
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events
Other bias Low risk Comment: no other bias noted
Lupo 2008  (Continued)
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Methods Randomised clinical trial
Participants Country: not stated
Period of recruitment: not stated
Number randomised: not stated
Post-randomisation dropouts: not stated
Revised sample size: not stated
Average age (years): not stated
Females: not stated
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not stated
Maintenance immunosuppression used during induction immunosuppression: cyclosporin A
Altered immunosuppression after withdrawal: no
Interventions Group 1: basiliximab + glucocorticosteroids (n = not stated)
Further details: basiliximab (no further details) + glucocorticosteroids (no further details)
Group 2: glucocorticosteroids (n = not stated)
Further details: glucocorticosteroids (no further details)
Outcomes None of the outcomes of interest were reported
Notes Source of funding (quote): "Sponsor: Novartis"
Trial name/trial registry number: NCT00343226
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





High risk Quote: "open"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: this information was not available
Selective reporting (re-
porting bias)
High risk Comment: although the trial completion date was 2005, no report is available
NCT 2006a 
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Methods Randomised clinical trial
Participants Country: multicentric (Europe and North America)
Period of recruitment: 1997-1998
Number randomised: 381
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 381
Average age (years): 50
Females: 140 (36.7%)
Primary transplantation: 381 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 82 (21.5%)
Viral-related cirrhosis: 132 (34.6%)
Autoimmune disease-related cirrhosis: 56 (14.7%)
HCC: 0 (0.0%)
Others: 111 (29.1%)
Maintenance immunosuppression used during induction immunosuppression: cyclosporin A
Altered immunosuppression after withdrawal: no (glucocorticosteroids were continued as mainte-
nance immunosuppression)
Other exclusion criteria:
• living donor liver transplant
• ABO blood group incompatibility
• multiple organ transplant
• fulminant liver failure
Interventions Group 1: basiliximab + glucocorticosteroids (n = 188)
Further details: basiliximab two 20 mg doses: first dose of basiliximab was administered within 6 hours
after reperfusion of the graH day 0, and the second dose, day 4 after transplantation + methyl pred-
nisolone 500 mg of intravenous methylprednisolone intraoperatively, followed by 200 mg of oral pred-
nisolone day 1. This dose was reduced by 40 mg/d over days 2 to 5 until 20 mg/d was reached, then ta-
pered over 6 months to a final dose of 10 mg/d
Group 2: glucocorticosteroids (n = 193)
Further details: methyl prednisolone 500 mg of intravenous methylprednisolone intraoperatively, fol-
lowed by 200 mg of oral prednisolone day 1. This dose was reduced by 40 mg/d over days 2 to 5 until 20
mg/d was reached, then tapered over 6 months to a final dose of 10 mg/d + placebo
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, serious adverse
events (number of people), any adverse events (number of people), graH rejection (any)
Follow-up (months): 12
Neuhaus 2002 
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Notes Source of funding (quote): "Supported in part by a grant from Novartis Pharma AG, Basel, Switzerland"
Trial name/trial registry number: CHIC 304
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A randomization schedule was computer generated by the sponsor for
each cohort, and patients were assigned a medication number indicating co-
hort, country, and medication sequence"
Allocation concealment
(selection bias)
Low risk Quote: "A randomization schedule was computer generated by the sponsor for
each cohort, and patients were assigned a medication number indicating co-





Low risk Quote: "double-blind, placebo-controlled "
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were no post-randomisation dropouts
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: multicentric (Europe)
Period of recruitment: 2005-2008
Number randomised: 138
Post-randomisation dropouts: 3 (2.2%)
Revised sample size: 135
Reasons for post-randomisation dropouts: not transplanted or no study medication
Average age (years): 54
Females: 41 (30.4%)
Primary transplantation: 135 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 0 (0.0%)
Viral-related cirrhosis: 135 (100.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: 0 (0.0%)
Others: 0 (0.0%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus
Altered immunosuppression after withdrawal: no
Neumann 2012 
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Interventions Group 1: daclizumab (n = 67)
Further details: daclizumab 2 mg/kg two doses: the first dose was given during the anhepatic period
and the second dose between days 7 and 10
Group 2: glucocorticosteroids (n = 68)
Further details: glucocorticosteroids (no further details) were given at a bolus dose of 500 mg in the pe-
rioperative period followed by tapered doses of 15-20 mg/day during month 1, 10-15 mg/day during
month 2, 5-10 mg/day during month 3, then discontinued
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, any adverse
events (number of people), graH rejection (any), graH rejection (requiring treatment)
Follow-up (months): 12
Notes Source of funding (quote): "Astellas Pharma Europe Ltd. provided funding for the study"
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Quote: "Allocation to treatment arms was performed using sealed sequentially





High risk Quote: "prospective, randomized, open-label, parallel arm study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 2006-2007
Number randomised: 40
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 40
Ramirez 2013 
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Average age (years): 53
Females: 15 (37.5%)
Primary transplantation: 40 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 9 (22.5%)
Viral-related cirrhosis: 29 (72.5%)
Autoimmune disease-related cirrhosis: 2 (5.0%)
HCC: 21 (52.5%)
Others: 5 (12.5%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• living donor liver transplant
• multiple organ transplant
Interventions Group 1: basiliximab (n = 20)
Further details: basiliximab 20 mg i.v. intraoperatively and on postoperative day 4
Group 2: basiliximab + glucocorticosteroids (n = 20)
Further details: basiliximab 20 mg i.v. intraoperatively and on postoperative day 4 + methylpred-
nisolone 1 g i.v. intraoperatively followed by a taper schedule as follows: methylprednisolone 50 mg i.v.
every six hours on day 1; 40 mg i.v. every six hours on day 2; 30 mg i.v. every six hours on day 3; 20 mg
i.v. every six hours on day 4; 20 mg i.v. every 12 hours on days 5; and thereafter, prednisone 20 mg PO
daily, which was tapered oB by six months post-OLT
Outcomes Outcomes reported: mortality at maximal follow-up
Follow-up (months): 64
Notes Source of funding (quote): "The authors would like to acknowledge Novartis Corporation for providing
financial grant to conduct the clinical trial"
Trial name/trial registry number: NCT00296244
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "based on the computer-generated randomization schedule "
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was performed by the TJUH Investigational Drug Phar-





High risk Quote: "prospective, controlled, randomized, non-blinded, pilot trial"
Blinding of outcome as-
sessment (detection bias) 
High risk Quote: "prospective, controlled, randomized, non-blinded, pilot trial"
Ramirez 2013  (Continued)
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Low risk Comment: although the authors excluded a patient from analysis, they re-




High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected





Methods Randomised clinical trial
Participants Country: Germany
Period of recruitment: 1997-2000
Number randomised: 100
Post-randomisation dropouts: 1 (1.0%)
Revised sample size: 99
Reasons for post-randomisation dropouts: not stated
Average age (years): 50
Females: 45 (45.5%)
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: 28 (28.3%)
Viral-related cirrhosis: 19 (19.2%)
Autoimmune disease-related cirrhosis: 17 (17.2%)
HCC: 13 (13.1%)
Others: 14 (14.1%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus
Altered immunosuppression after withdrawal: no (glucocorticosteroids were continued as mainte-
nance immunosuppression)
Interventions Group 1: basiliximab + glucocorticosteroids (n = 51)
Further details: basiliximab (day 0 and day 4: 20 mg each) + glucocorticosteroids (no further details)
Group 2: glucocorticosteroids (n = 48)
Further details: glucocorticosteroids (no further details)
Outcomes Outcomes reported: graH rejection (any)
Follow-up (months): 76
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Schmeding 2007 
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Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: Italy
Period of recruitment: not stated
Number randomised: 45
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 45
Average age (years): 50
Females: 11 (24.4%)
Primary transplantation: not stated
Reason for transplantation
Alcohol-related cirrhosis: 6 (13.3%)
Viral-related cirrhosis: 28 (62.2%)
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: 11 (24.4%)
Maintenance immunosuppression used during induction immunosuppression: cyclosporine A plus aza-
thioprine
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• HIV infection
Interventions Group 1: no active intervention (n = 23)
Further details: no active treatment
Group 2: glucocorticosteroids (n = 22)
Tisone 1999 
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Further details: methylprednisolone (20 mg/day) intravenous, followed by oral prednisone (20 mg/
day). Prednisone was gradually tapered from 20 mg to 5 mg, beginning from day 30 after transplanta-
tion, and was discontinued in all patients by the end of the third postoperative month
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, liver transplan-
tation at maximal follow-up, graH rejection (any)
Follow-up (months): 14
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomly assigned, using a computer-generated list"
Allocation concealment
(selection bias)





High risk Quote: "open-label randomized pilot study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: 1999
Number randomised: 30
Post-randomisation dropouts: not stated
Revised sample size: 30
Average age (years): 62
Females: 11 (36.7%)
Washburn 2001 
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Primary transplantation: 30 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 11 (36.7%)
Viral-related cirrhosis: 15 (50.0%)
Autoimmune disease-related cirrhosis: 0 (0.0%)
HCC: not stated
Others: 4 (13.3%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no (glucocorticosteroids were continued as mainte-
nance immunosuppression)
Other exclusion criteria:
• multiple organ transplant
Interventions Group 1: daclizumab + glucocorticosteroids (n = 15)
Further details: daclizumab (2 mg/kg i.v.) at the start of the operative procedure and 14 days after liv-
er transplantation+ methylprednisolone 500 mg intraoperatively and 500 mg on day 1 after liver trans-
plantation and then discontinued
Group 2: glucocorticosteroids (n = 15)
Further details: methylprednisolone was given as an intraoperative dose of 500 mg and a postoperative
taper starting at 200 mg to 30 mg by 7 days after transplantation. Patients were converted to oral cor-
ticosteroids when the daily dose was 80 mg or when they were able to tolerate liquids, whichever was
later. Corticosteroids were rapidly tapered to 5 mg by 3-4 weeks after transplantation. At 1 year, corti-
costeroids were generally tapered oB over 3 months
Outcomes Outcomes reported: mortality at maximal follow-up, graH failure at maximal follow-up, graH rejection
(any), graH rejection (requiring treatment)
Follow-up (months): 18
Notes Source of funding (quote): "This work was supported by Roche Laboratories, Inc."
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





High risk Quote: "randomized nonblinded study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "randomized nonblinded study"
Washburn 2001  (Continued)
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Unclear risk Comment: this information was not available
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected





Methods Randomised clinical trial
Participants Country: USA
Period of recruitment: not stated
Number randomised: 75
Post-randomisation dropouts: not stated
Revised sample size: 75
Average age (years): not stated
Females: not stated
Primary transplantation: 75 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
HCC: not stated
Others: not stated
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Interventions Group 1: anti-thymocyte globulin (n = 53)
Further details: anti-thymocyte globulin: target cumulative dose of 6 mg/kg given in 4 equally-divided
doses (no further details)
Group 2: glucocorticosteroids (n = 22)
Further details: glucocorticosteroids (no further details)
Outcomes Outcomes reported: mortality at maximal follow-up, graH rejection (any)
Follow-up (months): 6
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)
Unclear risk Comment: this information was not available
Washburn 2008 
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High risk Quote: "randomized, open-label, multicenter study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: this information was not available
Selective reporting (re-
porting bias)
High risk Comment: no pre-published protocol was available and the authors did not re-
port on adverse events adequately, even though it is clear that this informa-
tion was collected




Methods Randomised clinical trial
Participants Country: Canada
Period of recruitment: not stated
Number randomised: 148
Post-randomisation dropouts: 0 (0.0%)
Revised sample size: 148
Average age (years): 53
Females: 48 (32.4%)
Primary transplantation: 148 (100.0%)
Reason for transplantation
Alcohol-related cirrhosis: 29 (19.6%)
Viral-related cirrhosis: 56 (37.8%)
Autoimmune disease-related cirrhosis: 34 (23.0%)
HCC: not stated
Others: 29 (19.6%)
Maintenance immunosuppression used during induction immunosuppression: tacrolimus plus my-
cophenolate mofetil
Altered immunosuppression after withdrawal: no
Other exclusion criteria:
• living donor liver transplant
• ABO blood group incompatibility
Yoshida 2005 
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• multiple organ transplant
• serum creatinine > 180 micromol/L or dialysis
• fulminant liver failure
Interventions Group 1: daclizumab + glucocorticosteroids (n = 72)
Further details: daclizumab 2 mg/kg i.v. within 4 hours postoperatively and 1 mg/kg i.v. on postoper-
ative day 4 + methylprednisolone 500 mg i.v. intraoperatively, tapering to 20 mg i.v. on postoperative
day 5 followed by prednisone 5 mg/day orally. The prednisone was then tapered by 5 mg/month until
discontinuation after the month 3 post-transplant
Group 2: glucocorticosteroids (n = 76)
Further details: methylprednisolone 500 mg i.v. intraoperatively, tapering to 20 mg i.v. on postopera-
tive day 5 followed by prednisone 5 mg/day PO. The prednisone was then tapered by 5 mg/month until
discontinuation after the month 3 post-transplant
Outcomes Outcomes reported: mortality at maximal follow-up, serious adverse events (number of events), liver
transplantation at maximal follow-up, graH rejection (any)
Follow-up (months): 12
Notes Source of funding: not stated
Trial name/trial registry number: not stated
Attempts were made to contact the authors in August 2019.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: this information was not available
Allocation concealment
(selection bias)





Unclear risk Comment: this information was not available
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: there were post-randomisation dropouts. It was not clear whether
these could be related to the interventions
Selective reporting (re-
porting bias)
Low risk Comment: no pre-published protocol was available, but the authors reported
on mortality, graH loss, and adverse events




HCV: Hepatitis C virus
OLT: orthotopic liver transplantation
RNA: ribonucleic acid
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
EUCTR 2009 Not clear what interventions are used
Farges 1994 Not a comparison of interest for this review
Glanemann 1998 Not a comparison of interest for this review
Iesari 2018 Not a comparison of interest for this review
Ismail 1995 Not a comparison of interest for this review
ISRCTN 2010 Not clear what interventions are used
Jain 2002 Not a comparison of interest for this review
Klupp 1998 Not a comparison of interest for this review
Langrehr 1998 Not a comparison of interest for this review
Lerut 2008 Both groups received glucocorticosteroids; the duration of treatment was different between the
two groups
Liu 2013 Retrospective study where patients were randomly selected
Margarit 2005 Both groups received glucocorticosteroids; the duration of treatment was different between the
two groups
NCT 2005 A completed randomised clinical trial with no publication linked; it was not clear whether both
groups received thymoglobulin and glucocorticosteroids
NCT 2006b A completed randomised clinical trial with no publication linked; it was not clear whether both
groups received the same interventions, although the title suggests that they received different in-
terventions
NCT 2007 Not a comparison of interest for this review
NCT 2017 Both groups received glucocorticosteroids; the type of steroids was different between the two
groups
Neuberger 2009 Glucocorticosteroids were given according to local practice; therefore not clear if all participants
received glucocorticosteroids
Pelletier 2005 A proportion of participants in both groups received basiliximab, which was not decided by ran-
dom
Reding 1993 Not a comparison of interest for this review
Russell 2016 The other immunosuppressive drugs were different in the two groups, i.e. the co-interventions
were different in the two groups
Saliba 2016 Both groups received glucocorticosteroids; the duration of treatment was different between the
two groups
Samuel 1998 Not a comparison of interest for this review
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Study Reason for exclusion
Serrano 2002 Not a comparison of interest for this review
Trunecka 2015 Optional glucocorticosteroids were given to the participants; since glucocorticosteroids is one of
the interventions of interest for this network meta-analysis and the decision to give glucocorticos-
teroids was not decided at random, we excluded this study
Turner 2006 There is mention about use or not use of glucocorticosteroids at the time of induction of anaesthe-
sia; there is no information about the subsequent immunosuppressive regimen, which might have
included steroids in both groups
Tzakis 2004 Not a randomised clinical trial
 



















Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title NCT02123108
Methods Randomised controlled trial
Participants Patients undergoing liver transplantation
NCT02123108 
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Interventions Basiliximab plus glucocorticosteroids versus glucocorticosteroids alone
Outcomes Death, graH failure, adverse events, graH rejection
Starting date January 2011
Contact information Fady M Kaldas (fkaldas@mednet.ucla.edu)




Trial name or title NCT02544113
Methods Randomised controlled trial
Participants Patients undergoing liver transplantation
Interventions Thymoglobulin plus glucocorticosteroids versus glucocorticosteroids alone
Outcomes GraH failure, graH rejection
Starting date December 2015
Contact information Bijan Eghtesad, The Cleveland Clinic




A D D I T I O N A L   T A B L E S
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3604817.
Table 1.   Potential eGect modifiers (ordered by comparison) 
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Klintmalm 2014 Basiliximab + glucocorti-
costeroids
Glucocorticosteroids Low Low Low Low Unclear Low High
NCT 2006a Basiliximab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear High High Unclear High High
Neuhaus 2002 Basiliximab + glucocorti-
costeroids
Glucocorticosteroids Low Low Low Low Low Low Low
Schmeding 2007 Basiliximab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear Unclear Unclear Unclear High High
Benitez 2010 Anti-thymocyte globulin
+ glucocorticosteroids
Glucocorticosteroids Low Low High High Low Low High
Bogetti 2005 Anti-thymocyte globulin
+ glucocorticosteroids
Glucocorticosteroids Unclear Unclear Unclear Unclear Unclear High High
Boillot 2009 Anti-thymocyte globulin
+ glucocorticosteroids
Glucocorticosteroids Low Unclear High High Low Low High
Kathirvel 2018 Basiliximab Glucocorticosteroids Unclear Unclear Unclear Unclear Low High High
Lupo 2008 Basiliximab Glucocorticosteroids Low Low Unclear Unclear Low Low High
Filipponi 2004 Basiliximab Basiliximab + glucocorticosteroids Low Low Low Low Low High High
Llado 2006 Basiliximab Basiliximab + glucocorticosteroids Unclear Low High High Unclear Low High
Ramirez 2013 Basiliximab Basiliximab + glucocorticosteroids Low Low High High Low High High
Boillot 2005 Daclizumab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear High High Unclear Low High





























































































































































Calmus 2010 Daclizumab + glucocorti-
costeroids
Glucocorticosteroids Low Low High High High Low High
Lu 2006 Daclizumab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear Unclear Unclear Low High High
Washburn 2001 Daclizumab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear High High Unclear High High
Yoshida 2005 Daclizumab + glucocorti-
costeroids
Glucocorticosteroids Unclear Unclear Unclear Unclear Low Low High
Eason 2003 Anti-thymocyte globulin Glucocorticosteroids Unclear Unclear Unclear Unclear Low High High
Washburn 2008 Anti-thymocyte globulin Glucocorticosteroids Unclear Unclear High High Unclear High High
Belli 2001 Anti-thymocyte globulin Anti-thymocyte globulin + glucocor-
ticosteroids
Unclear Unclear Unclear Unclear Unclear High High
Garcia-Saenz-De-
Sicilia 2014
Anti-thymocyte globulin Anti-thymocyte globulin + glucocor-
ticosteroids
Unclear Unclear High High Unclear High High
Kato 2007 Daclizumab Glucocorticosteroids Unclear Unclear Unclear Low High High High
Klintmalm 2011 Daclizumab Glucocorticosteroids Unclear Unclear High High Unclear High High
Neumann 2012 Daclizumab Glucocorticosteroids Low Low High High Unclear Low High
Tisone 1999 No active intervention Glucocorticosteroids Low Unclear High High Low High High
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Mortality at maximal follow-up Fixed-effect model Random-effects model Inconsistency model
Dbar 147.7 145.2 145.9
DIC 170.3 171.5 174.3
pD 22.6 26.27 28.42
Gra4 failure at maximal follow-up Fixed-effect model Random-effects model Inconsistency model
Dbar 99.92 86.36 86.58
DIC 115.7 107.1 106.2
pD 15.8 20.77 19.57
Serious adverse events (number of
people)
Fixed-effect model Random-effects model Inconsistency model
Dbar 52.9 51.55 -
DIC 58.88 58.36 -
pD 5.979 6.815 -
Any adverse events (number of peo-
ple)
Fixed-effect model Random-effects model Inconsistency model
Dbar 32.86 33.35 -
DIC 39.53 40.7 -
pD 6.67 7.353 -
Liver transplantation at maximal fol-
low-up
Fixed-effect model Random-effects model Inconsistency model
Dbar 31.16 31.76 -
DIC 36.83 38.52 -
pD 5.665 6.758 -
Gra4 rejection (any) Fixed-effect model Random-effects model Inconsistency model
Dbar 212.4 211.1 211.5
DIC 241.3 242.9 245.3
pD 28.91 31.81 33.8
Gra4 rejection (requiring treatment) Fixed-effect model Random-effects model Inconsistency model
Dbar 56.06 56.73 -
Table 3.   Model fit 
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DIC 67.01 68.17 -
pD 10.95 11.44 -
Table 3.   Model fit  (Continued)
Abbreviations
Dbar = posterior mean of deviance
DIC = deviance information criteria
pD = eBective number of parameters or leverage
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Glucocorticosteroids - 0.75[0.13,3.37] 1.53[0.02,67.90] 0.50[0.02,12.55]1.36[0.63,3.88]1.35[0.04,84.69]1.64[0.03,114.78]0.76[0.21,2.62]
Basiliximab + gluco-
corticosteroids




1.72[0.70,4.28] 2.41[0.89,6.89] - - - 0.72[0.26,2.00]- -
Basiliximab 0.53[0.31,0.93] 0.74[0.41,1.41] 0.31[0.11,0.89] - - - - -
Daclizumab + gluco-
corticosteroids
1.33[0.78,2.43] 1.87[0.92,4.21] 0.77[0.27,2.26] 2.53[1.16,5.66]- - - -
Anti-thymocyte globu-
lin
1.20[0.58,2.59] 1.67[0.71,4.30] 0.70[0.28,1.80] 2.27[0.91,5.73]0.90[0.35,2.26]- - -
Daclizumab 1.29[0.60,3.06] 1.80[0.75,5.09] 0.75[0.24,2.62] 2.44[0.95,6.72]0.96[0.37,2.67]1.08[0.38,3.33]- -
No active intervention 0.75[0.18,3.13] 1.06[0.23,4.79] 0.44[0.08,2.35] 1.42[0.31,6.48]0.57[0.12,2.52]0.62[0.12,3.08]0.58[0.11,2.83]-

























Glucocorticosteroids - 0.71[0.11,4.25] 1.93[0.05,91.47] 0.44[0.28,0.70]1.36[0.18,49.90].90[0.51,1.59]1.24[0.03,57.17]0.76[0.22,2.61]
Basiliximab + gluco-
corticosteroids




1.95[0.47,8.36] 3.54[0.69,18.71] - - - - - -
Basiliximab 0.81[0.31,2.17] 1.48[0.64,3.64] 0.42[0.07,2.38] - - - - -































































































































































1.27[0.49,3.75] 2.31[0.70,8.92] 0.66[0.12,4.00] 1.57[0.41,6.59]- - - -
Anti-thymocyte globu-
lin
0.89[0.21,3.88] 1.63[0.32,8.61] 0.46[0.06,3.48] 1.11[0.19,6.17]0.70[0.11,3.89]- - -
Daclizumab 1.21[0.43,3.77] 2.19[0.63,8.85] 0.62[0.10,3.85] 1.48[0.36,6.76]0.95[0.21,4.13]1.34[0.23,8.65]- -















































Glucocorticosteroids - 0.97[0.02,39.21] 1.01[0.54,1.88] 0.28[0.04,1.32]
Basiliximab + gluco-
corticosteroids
0.98[0.02,38.67] - - -
-































































































































































1.01[0.53,1.90] 1.03[0.02,41.85] - -





















Basiliximab Daclizumab + gluco-
corticosteroids
Glucocorticosteroids - 0.79[0.02,31.94] 1.25[0.67,2.43]





























Glucocorticosteroids - 0.90[0.65,1.24] 1.49[0.66,3.44] 0.60[0.24,1.44]0.96[0.73,1.26]0.91[0.46,1.81]0.62[0.37,1.02]0.95[0.02,38.78]
Basiliximab + gluco-
corticosteroids




1.42[0.69,2.95] 1.68[0.77,3.73] - - - 0.75[0.17,3.04]- -





























































































































































Basiliximab 0.91[0.49,1.67] 1.07[0.59,1.96] 0.64[0.24,1.64] - - - - -
Daclizumab + gluco-
corticosteroids
0.96[0.73,1.25] 1.13[0.75,1.71] 0.67[0.31,1.45] 1.05[0.55,2.05]- - - -
Anti-thymocyte globu-
lin
0.93[0.49,1.76] 1.10[0.54,2.23] 0.66[0.28,1.53] 1.03[0.42,2.49]0.97[0.49,1.94]- - -
Daclizumab 0.62[0.38,1.02] 0.73[0.41,1.32] 0.44[0.18,1.05] 0.68[0.31,1.51]0.65[0.37,1.14]0.67[0.30,1.50]- -


















Glucocorticosteroids - 1.21[0.52,2.73] 0.44[0.09,1.89] 0.94[0.67,1.32]1.77[0.39,9.66]1.02[0.33,3.23]
Basiliximab + gluco-
corticosteroids
1.21[0.52,2.72] - - - - -
Basiliximab 0.43[0.09,1.85] 0.36[0.06,1.90] - - - -
Daclizumab + gluco-
corticosteroids
0.94[0.67,1.31] 0.78[0.32,1.94] 2.17[0.49,10.29] - - -
Anti-thymocyte globu-
lin
1.76[0.40,9.98] 1.49[0.27,9.68] 4.17[0.51,40.04] 1.89[0.41,11.00]- -
Daclizumab 1.02[0.32,3.13] 0.85[0.21,3.50] 2.37[0.37,15.50] 1.08[0.32,3.50]0.57[0.07,3.71]-
-
Table 4.   EGect estimates when network meta-analysis was performed  (Continued)
The table provides the eBect estimates. The top half of the subtable for each outcome indicates the eBect estimates from the direct comparisons. The bottom half of the subtable
for each outcome indicates the eBect estimates from the network meta-analysis. For network meta-analysis, to identify the eBect estimate of a comparison, say A versus B, look
at the cell that occupies the row corresponding to intervention A and the column corresponding to intervention B for the direct eBect estimate. If that cell is empty (indicated by
a '-'), look at the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the treatment
eBect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column corresponding to intervention A and the row corresponding
to intervention B for the direct eBect estimate. If that cell is empty, look at the column corresponding to intervention B and the row corresponding to intervention A. Take the
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A P P E N D I C E S
Appendix 1. Search strategies
 





Issue 7, 2019 #1 (liver or hepatic)
#2 (transplant* or graH*)
#3 #1 and #2
#4 MeSH descriptor: [Liver Transplantation] explode all trees
#5 #3 or #4
#6 immunosuppress*
#7 MeSH descriptor: [Immunosuppression] explode all trees
#8 MeSH descriptor: [Immunosuppressive Agents] explode all trees
#9 #6 or #7 or #8
#10 MeSH descriptor: [Glucocorticoids] explode all trees
#11 MeSH descriptor: [Antilymphocyte Serum] explode all trees
#12 (corticosteroids or glucocorticoids or prednisolone or prednisone or methylpred-
nisolone or cortisol or cortisone or methylprednisolone or betamethasone or thymoglob-
ulin or antithymocyte or antilymphocyte or anti-thymocyte or thymocyte antibody or an-
ti-lymphocyte or alemtuzumab or basiliximab or daclizumab)
#13 #10 or #11 or #12
#14 #5 and #9 and #13
MEDLINE Ovid January 1947 to
July 2019
1. (liver or hepatic).af.
2. (transplant* or graH*).af.
3. 1 and 2
4. exp Liver Transplantation/
5. 3 or 4
6. exp Immunosuppression/ or exp Immunosuppressive Agents/
7. immunosuppress*.ti,ab.
8. 6 or 7
9. exp Glucocorticoids/
10. exp Antilymphocyte Serum/
11. (corticosteroids or glucocorticoids or prednisolone or prednisone or methylpred-
nisolone or cortisol or cortisone or methylprednisolone or betamethasone or thymoglob-
ulin or antithymocyte or antilymphocyte or anti-thymocyte or thymocyte antibody or an-
ti-lymphocyte or alemtuzumab or basiliximab or daclizumab).ti,ab.
12. or/9-11
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13. 5 and 8 and 12
14. randomized controlled trial.pt.







22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. exp animals/ not humans.sh.
24. 22 not 23
25. 13 and 24
Embase Ovid January 1974 to
July 2019
1. (liver or hepatic).af.
2. (transplant* or graH*).af.
3. 1 and 2
4. exp liver transplantation/
5. 3 or 4
6. exp immunosuppressive treatment/ or exp immunosuppressive agent/
7. immunosuppress*.ti,ab.
8. 6 or 7
9. exp glucocorticoid/
10. exp thymocyte antibody/
11. (corticosteroids or glucocorticoids or prednisolone or prednisone or methylpred-
nisolone or cortisol or cortisone or methylprednisolone or betamethasone or thymoglob-
ulin or antithymocyte or antilymphocyte or anti-thymocyte or thymocyte antibody or an-
ti-lymphocyte or alemtuzumab or basiliximab or daclizumab).ti,ab.
12. or/9-11
13. 5 and 8 and 12
14. exp crossover-procedure/ or exp double-blind procedure/ or exp randomized con-
trolled trial/ or single-blind procedure/
15. (((((random* or factorial* or crossover* or cross over* or cross-over* or placebo* or
double*) adj blind*) or single*) adj blind*) or assign* or allocat* or volunteer*).af.
16. 14 or 15
17. 13 and 16
  (Continued)
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#1 TS=((liver or hepatic) AND (transplant* or graH*))
#2 TS=(immunosuppress*)
#3 TS=(corticosteroids or glucocorticoids or prednisolone or prednisone or methylpred-
nisolone or cortisol or cortisone or methylprednisolone or betamethasone or thymoglob-
ulin or antithymocyte or antilymphocyte or anti-thymocyte or thymocyte antibody or an-
ti-lymphocyte or alemtuzumab or basiliximab or daclizumab)
#4 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analy-
sis OR systematic review* OR meta-analys*)









July 2019 liver transplant* AND immunosuppress*













This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3605013.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. We analysed graH rejections (any) and graH rejections requiring treatment as time-to-event outcomes because the trials reported this
information at maximal follow-up rather than at three months.
2. We used 'glucocorticosteroids' as the reference treatment (rather than no induction immunosuppression) as this was the commonest
control group used in the trials and is currently considered as the 'standard of care' for induction immunosuppression.
3. We did not perform Trial Sequential Analysis (TSA) because the risk of false positive results with Bayesian meta-analysis is probably
less or at least equivalent to TSA.
4. We used the latest guidance from the GRADE Working group (Yepes-Nunez 2019), rather than the previous guidance (Puhan 2014), for
presenting the 'Summary of findings' tables.
5. We used 30,000 iterations (instead of 10,000 iterations) as a minimum for burn-in of the simulation sampler used to estimate quantities
in the statistical models to ensure convergence of the simulation sampler.
6. We did not present some information, such as ranking probability tables, rankograms, and surface area under the curve (SUCRA plots)
due to concern regarding misinterpretation of the results. We have highlighted this clearly within the text of the review along with the
reasons for not presenting them.
N O T E S
The methods section of this review is based on a standard Cochrane Hepato-Biliary template, incorporating advice by the Complex Reviews
Support Unit for a network meta-analysis protocol (Best 2018).
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